search in electronic databases (n=1558) pubmed: 760 embase: 795 web of science: 3
DESCRIPTION
Supplementary Figure 1. Study flow diagram. Search in electronic databases (n=1558) PubMed: 760 Embase: 795 Web of Science: 3. Hand-searching (n=21). Retrieved (n=1579). Excluded duplicates (n=797). Title review (n=782). Excluded; no relevance (n=441). Abstract review (n=341) - PowerPoint PPT PresentationTRANSCRIPT
Search in electronic databases (n=1558)PubMed: 760Embase: 795Web of Science: 3
Retrieved (n=1579)
Hand-searching(n=21)
Title review (n=782)
Abstract review (n=341)
Article review for more detailed evaluation (n=117)
Included 79 studies in 75 articles
Excluded duplicates(n=797)
Excluded; no relevance(n=441)
Articles excluded (n=42)For reasons see Supplementary Table 1
Supplementary Figure 1. Study flow diagram
Supplementary Figure 2. Detailed meta-analysis of Arg702Trp on the basis of allele frequencies. Crohn’s disease. All studies.
Random effectFixed effect
Hugot JP (2001)
Hampe J (2002)
Study
Ernst A (2007)Cavanaugh JA (2003)
Canto E (2007)
Heresbach D (2004)
Karban A (2005)
Nunez C (2004)
Newman B (2004)
Karban A (2005)
Arnot IDR (2004)
Tukel T (2004)Ince AT (2008)
Weersma RK (2009)
Leung E (2005)
Bene J (2006)
Oostenbrug LE (2006)
Jess T (2005)
Vermeire S (2002)
Ahmad T (2002)
Zouiten-Mekki L (2005)
Cottone M (2006)
Riss L (2007)
Giachino D (2004)
Brant SR (2007)
Ferraris A (2006)
Lakatos PL (2005)Baptista ML (2008)
Vermeire S (2004)
Crawford NPS (2007)
Protic MB (2007)
Esters N (2004)
Mendoza JL (2003)
Russel RK (2005)Cukovic-Cavak S (2006)
Tomer G (2003)
Lappalainen M (2008)
Sugimura K (2003)
Economou M (2007)
Torkvist L (2006)
van der Linde K (2007)
Tukel T (2004)
Braat H (2005)Diego CD (2006)
Nagy Z (2005)
Magyari L (2009)
Vind I (2005)
de Ridder L (2007)
Cucchiara S (2007)Kugathasan S (2005)
Bonen DK (2003)
Bianchi V (2007)
Buhner S (2006)Karban A (2004)
Zhou Z (2002)
Hradsky O (2008)
Cuthbert AP (2002)
Rigoli L (2008)
Ozen SC (2006)
Annese V (2005)
Buning C (2005)
Gazouli M (2004)
Helio T (2003)
Rodrigo L (2007)
Zaahl MG (2005)
Vavassori P (2004)
Kugathasan S (2005)
Mascheretti S (2002)
Ferreira AC (2005)
Kugathasan S (2005)
Derakhshan F (2008)
Gearry RB (2007)
2.24 (2.03, 2.48)
3.06 (1.47, 6.39)
2.72 (1.92, 3.84)
2.02 (1.32, 3.09)2.35 (1.56, 3.56)
6.59 (1.52, 28.55)
2.60 (1.25, 5.43)
4.24 (1.46, 12.30)
1.17 (0.62, 2.20)
2.26 (1.31, 3.90)
5.58 (0.23, 137.89)
1.48 (0.88, 2.51)
6.71 (1.04, 43.16)0.16 (0.02, 1.26)
1.65 (1.33, 2.04)
1.47 (0.80, 2.69)
1.89 (0.58, 6.10)
1.88 (1.21, 2.92)
3.76 (1.11, 12.80)
3.38 (1.43, 8.01)
2.63 (1.71, 4.04)
3.51 (0.41, 30.30)
OR (95% CI)
2.98 (1.33, 6.70)
2.31 (1.50, 3.57)
1.56 (0.89, 2.76)
3.49 (2.08, 5.86)
4.51 (1.91, 10.64)
2.55 (1.37, 4.73)3.77 (2.00, 7.10)
2.94 (1.74, 4.96)
5.50 (1.67, 18.18)
1.50 (0.90, 2.50)
2.42 (1.48, 3.97)
3.52 (1.70, 7.26)
1.19 (0.58, 2.43)2.79 (1.35, 5.76)
5.47 (1.48, 20.16)
2.15 (0.83, 5.55)
1.73 (1.10, 2.73)
3.85 (1.25, 11.93)
6.68 (1.52, 29.31)
1.53 (0.68, 3.45)
2.11 (0.92, 4.84)
2.89 (1.47, 5.65)2.29 (1.15, 4.58)
2.30 (1.00, 5.27)
1.41 (0.66, 3.03)
1.01 (0.41, 2.49)
2.96 (1.77, 4.93)
3.01 (1.83, 4.95)1.26 (0.76, 2.07)
1.95 (1.26, 3.04)
1.79 (0.94, 3.42)
3.15 (1.06, 9.32)4.13 (1.38, 12.34)
1.13 (0.56, 2.26)
1.48 (0.95, 2.30)
2.72 (1.64, 4.50)
4.36 (1.64, 11.55)
0.75 (0.14, 4.17)
2.20 (1.26, 3.85)
2.81 (1.33, 5.92)
11.00 (2.57, 47.14)
1.84 (0.86, 3.93)
0.79 (0.36, 1.72)
2.10 (0.62, 7.08)
1.52 (0.28, 8.37)
0.53 (0.06, 4.80)
2.05 (1.33, 3.14)
3.31 (2.03, 5.38)
0.44 (0.02, 7.89)
9.51 (3.00, 30.16)
2.59 (1.41, 4.76)
1.31
2.97
2.502.57
0.42
1.31
0.73
1.61
1.93
0.09
2.02
0.270.22
3.81
1.71
0.62
2.44
0.58
1.04
2.48
0.20
Weight, %
1.14
2.46
1.85
2.05
1.04
1.661.61
2.03
0.60
2.08
2.16
1.34
1.371.34
0.52
0.89
2.35
0.66
0.41
1.13
1.09
1.491.43
1.10
1.24
0.96
2.08
2.142.14
2.42
1.57
0.710.70
1.42
2.43
2.11
0.85
0.32
1.88
1.29
0.42
1.25
1.20
0.59
0.32
0.20
2.50
2.20
0.12
0.64
1.69
2.24 (2.03, 2.48)
3.06 (1.47, 6.39)
2.72 (1.92, 3.84)
2.02 (1.32, 3.09)2.35 (1.56, 3.56)
6.59 (1.52, 28.55)
2.60 (1.25, 5.43)
4.24 (1.46, 12.30)
1.17 (0.62, 2.20)
2.26 (1.31, 3.90)
5.58 (0.23, 137.89)
1.48 (0.88, 2.51)
6.71 (1.04, 43.16)0.16 (0.02, 1.26)
1.65 (1.33, 2.04)
1.47 (0.80, 2.69)
1.89 (0.58, 6.10)
1.88 (1.21, 2.92)
3.76 (1.11, 12.80)
3.38 (1.43, 8.01)
2.63 (1.71, 4.04)
3.51 (0.41, 30.30)
2.98 (1.33, 6.70)
2.31 (1.50, 3.57)
1.56 (0.89, 2.76)
3.49 (2.08, 5.86)
4.51 (1.91, 10.64)
2.55 (1.37, 4.73)3.77 (2.00, 7.10)
2.94 (1.74, 4.96)
5.50 (1.67, 18.18)
1.50 (0.90, 2.50)
2.42 (1.48, 3.97)
3.52 (1.70, 7.26)
1.19 (0.58, 2.43)2.79 (1.35, 5.76)
5.47 (1.48, 20.16)
2.15 (0.83, 5.55)
1.73 (1.10, 2.73)
3.85 (1.25, 11.93)
6.68 (1.52, 29.31)
1.53 (0.68, 3.45)
2.11 (0.92, 4.84)
2.89 (1.47, 5.65)2.29 (1.15, 4.58)
2.30 (1.00, 5.27)
1.41 (0.66, 3.03)
1.01 (0.41, 2.49)
2.96 (1.77, 4.93)
3.01 (1.83, 4.95)1.26 (0.76, 2.07)
1.95 (1.26, 3.04)
1.79 (0.94, 3.42)
3.15 (1.06, 9.32)4.13 (1.38, 12.34)
1.13 (0.56, 2.26)
1.48 (0.95, 2.30)
2.72 (1.64, 4.50)
4.36 (1.64, 11.55)
0.75 (0.14, 4.17)
2.20 (1.26, 3.85)
2.81 (1.33, 5.92)
11.00 (2.57, 47.14)
1.84 (0.86, 3.93)
0.79 (0.36, 1.72)
2.10 (0.62, 7.08)
1.52 (0.28, 8.37)
0.53 (0.06, 4.80)
2.05 (1.33, 3.14)
3.31 (2.03, 5.38)
0.44 (0.02, 7.89)
9.51 (3.00, 30.16)
2.59 (1.41, 4.76)
1.31
2.97
2.502.57
0.42
1.31
0.73
1.61
1.93
0.09
2.02
0.270.22
3.81
1.71
0.62
2.44
0.58
1.04
2.48
0.20
1.14
2.46
1.85
2.05
1.04
1.661.61
2.03
0.60
2.08
2.16
1.34
1.371.34
0.52
0.89
2.35
0.66
0.41
1.13
1.09
1.491.43
1.10
1.24
0.96
2.08
2.142.14
2.42
1.57
0.710.70
1.42
2.43
2.11
0.85
0.32
1.88
1.29
0.42
1.25
1.20
0.59
0.32
0.20
2.50
2.20
0.12
0.64
1.69
1.05 1 5 10 50
Crohn’s disease
Odds ratio (95% CI)
2.21 (2.06, 2.37)
Supplementary Figure 3. Detailed meta-analysis of Gly908Arg on the basis of allele frequencies. Crohn’s disease. All studies.
Random effectFixed effect
Vind I (2005)
Ince AT (2008)
Ferreira AC (2005)
Sugimura K (2003)
Zouiten-Mekki L (2005)
Buhner S (2006)
Torkvist L (2006)
Ferraris A (2006)
Tukel T (2004)
Bonen DK (2003)
Tomer G (2003)
Kugathasan S (2005)
Canto E (2007)
Protic MB (2007)
Braat H (2005)
Annese V (2005)
Esters N (2004)
Magyari L (2009)
Ernst A (2007)
Newman B (2004)
Leung E (2005)
Rigoli L (2008)
Rodrigo L (2007)
Kugathasan S (2005)
Riss L (2007)Lakatos PL (2005)
Jess T (2005)
Cukovic-Cavak S (2006)
Vermeire S (2002)
Nunez C (2004)
Study
Crawford NPS (2007)
Cavanaugh JA (2003)
Lappalainen M (2008)
Karban A (2004)
van der Linde K (2007)
Hradsky O (2008)
Baptista ML (2008)
Ozen SC (2006)
Ahmad T (2002)
Diego CD (2006)Buning C (2005)
Arnot IDR (2004)
Derakhshan F (2008)
Cuthbert AP (2002)
Bene J (2006)
Mendoza JL (2003)
Cucchiara S (2007)
Hugot JP (2001)
Oostenbrug LE (2006)
Giachino D (2004)
Heresbach D (2004)
Zaahl MG (2005)
Gazouli M (2004)
Hampe J (2002)
de Ridder L (2007)
Bianchi V (2007)
Zhou Z (2002)
Queiroz DM, (2009)
Karban A (2005)
Weersma RK (2009)
Brant SR (2007)
Karban A (2005)
Vavassori P (2004)
Kugathasan S (2005)
Vermeire S (2004)
Cottone M (2006)
Nagy Z (2005)
Mascheretti S (2002)
Helio T (2003)
Economou M (2007)
Gearry RB (2007)
Russel RK (2005)
Tukel T (2004)
2.56 (2.23, 2.94)
3.11 (0.69, 14.06)
0.65 (0.06, 7.21)
OR (95% CI)
2.19 (0.90, 5.33)
1.58 (0.95, 2.63)
1.99 (0.70, 5.63)
2.63 (0.57, 12.19)
12.30 (0.70, 216.21)
6.89 (2.33, 20.32)
2.50 (1.30, 4.78)
3.31 (1.80, 6.10)
1.96 (0.98, 3.93)
4.27 (2.23, 8.17)
5.83 (0.32, 106.57)
20.60 (1.22, 347.57)
1.11 (0.59, 2.09)
2.85 (1.46, 5.56)
3.43 (1.47, 7.97)
8.20 (1.83, 36.73)
1.55 (0.73, 3.29)
1.52 (0.80, 2.91)
1.48 (0.62, 3.50)
1.03 (0.43, 2.50)
1.20 (0.24, 5.99)
0.96 (0.05, 18.98)
1.21 (0.53, 2.76)1.76 (0.77, 4.02)
2.31 (0.38, 14.24)
4.15 (0.92, 18.78)
7.73 (1.04, 57.63)
5.19 (1.49, 18.10)
2.30 (0.66, 8.06)
2.13 (0.85, 5.33)
3.98 (0.19, 83.06)
7.00 (3.12, 15.69)
9.88 (1.29, 75.93)
2.82 (1.55, 5.12)
1.20 (0.43, 3.33)
2.30 (0.38, 13.94)
2.33 (1.05, 5.18)
2.63 (0.83, 8.35)2.58 (0.85, 7.77)
7.10 (0.93, 54.19)
5.21 (0.94, 29.04)
6.71 (2.03, 22.14)
6.28 (0.78, 50.38)
4.64 (1.62, 13.25)
2.97 (1.63, 5.42)
6.49 (1.57, 26.82)
1.42 (0.83, 2.45)
3.17 (1.15, 8.76)
2.37 (0.68, 8.28)
0.81 (0.03, 19.99)
4.55 (1.97, 10.51)
5.72 (2.91, 11.25)
1.31 (0.78, 2.22)
4.79 (1.37, 16.71)
1.57 (0.84, 2.94)
5.23 (1.61, 17.04)
1.87 (0.37, 9.39)
2.05 (1.49, 2.82)
4.06 (1.69, 9.73)
5.76 (2.59, 12.81)
2.66 (0.97, 7.31)2.10 (0.81, 5.42)
4.01 (1.61, 9.99)
1.95 (0.43, 8.86)
2.52 (1.41, 4.51)
7.79 (0.40, 151.18)
0.84 (0.39, 1.79)
2.21 (0.86, 5.65)
11.20 (0.64, 197.01)
7.52 (1.90, 29.85)
0.72
0.31
1.64
3.00
1.31
0.70
0.22
1.24
2.40
2.55
2.23
2.40
0.22
0.23
2.45
2.32
1.76
0.73
2.03
2.40
1.71
1.65
0.65
0.21
1.801.81
0.52
0.72
0.43
0.99
0.98
1.57
0.20
1.86
0.42
2.61
1.35
0.53
1.89
1.121.20
0.43
0.58
1.06
0.41
1.29
2.59
0.80
2.85
1.36
0.99
0.18
1.78
2.29
2.94
0.99
2.49
1.08
0.64
3.99
1.68
1.89
1.37
0.00
1.50
1.58
0.72
2.68
0.21
2.00
1.52
0.22
0.84
2.56 (2.23, 2.94)
3.11 (0.69, 14.06)
0.65 (0.06, 7.21)
2.19 (0.90, 5.33)
1.58 (0.95, 2.63)
1.99 (0.70, 5.63)
2.63 (0.57, 12.19)
12.30 (0.70, 216.21)
6.89 (2.33, 20.32)
2.50 (1.30, 4.78)
3.31 (1.80, 6.10)
1.96 (0.98, 3.93)
4.27 (2.23, 8.17)
5.83 (0.32, 106.57)
20.60 (1.22, 347.57)
1.11 (0.59, 2.09)
2.85 (1.46, 5.56)
3.43 (1.47, 7.97)
8.20 (1.83, 36.73)
1.55 (0.73, 3.29)
1.52 (0.80, 2.91)
1.48 (0.62, 3.50)
1.03 (0.43, 2.50)
1.20 (0.24, 5.99)
0.96 (0.05, 18.98)
1.21 (0.53, 2.76)1.76 (0.77, 4.02)
2.31 (0.38, 14.24)
4.15 (0.92, 18.78)
7.73 (1.04, 57.63)
5.19 (1.49, 18.10)
2.30 (0.66, 8.06)
2.13 (0.85, 5.33)
3.98 (0.19, 83.06)
7.00 (3.12, 15.69)
9.88 (1.29, 75.93)
2.82 (1.55, 5.12)
1.20 (0.43, 3.33)
2.30 (0.38, 13.94)
2.33 (1.05, 5.18)
2.63 (0.83, 8.35)2.58 (0.85, 7.77)
7.10 (0.93, 54.19)
5.21 (0.94, 29.04)
6.71 (2.03, 22.14)
6.28 (0.78, 50.38)
4.64 (1.62, 13.25)
2.97 (1.63, 5.42)
6.49 (1.57, 26.82)
1.42 (0.83, 2.45)
3.17 (1.15, 8.76)
2.37 (0.68, 8.28)
0.81 (0.03, 19.99)
4.55 (1.97, 10.51)
5.72 (2.91, 11.25)
1.31 (0.78, 2.22)
4.79 (1.37, 16.71)
1.57 (0.84, 2.94)
5.23 (1.61, 17.04)
1.87 (0.37, 9.39)
2.05 (1.49, 2.82)
4.06 (1.69, 9.73)
5.76 (2.59, 12.81)
2.66 (0.97, 7.31)
2.10 (0.81, 5.42)
4.01 (1.61, 9.99)
1.95 (0.43, 8.86)
2.52 (1.41, 4.51)
7.79 (0.40, 151.18)
0.84 (0.39, 1.79)
2.21 (0.86, 5.65)
11.20 (0.64, 197.01)
7.52 (1.90, 29.85)
0.72
0.31
1.64
3.00
1.31
0.70
0.22
1.24
2.40
2.55
2.23
2.40
0.22
0.23
2.45
2.32
1.76
0.73
2.03
2.40
1.71
1.65
0.65
0.21
1.801.81
0.52
0.72
0.43
0.99
0.98
1.57
0.20
1.86
0.42
2.61
1.35
0.53
1.89
1.121.20
0.43
0.58
1.06
0.41
1.29
2.59
0.80
2.85
1.36
0.99
0.18
1.78
2.29
2.94
0.99
2.49
1.08
0.64
3.99
1.68
1.89
1.37
0.00
1.50
1.58
0.72
2.68
0.21
2.00
1.52
0.22
0.84
1.05 5 10 50
Crohn’s disease Weight, %
Odds ratio (95% CI)
(Excluded)
2.56 (2.31, 2.83)
Studies were excluded from meta-analysis if the risk allele/genotype was found neither in cases nor in controls.
Supplementary Figure 4. Detailed meta-analysis of Leu1007fsincC on the basis of allele frequencies. Crohn’s disease. All studies..
Random effect
Fixed effect
Ahmad T (2002)
Gearry RB (2007)Hugot JP (2001)
Arnot IDR (2004)
Buning C (2005)
Economou M (2007)
Tomer G (2003)Helio T (2003)
Zouiten-Mekki L (2005)
Crawford NPS (2007)
Mascheretti S (2002)
Heresbach D (2004)
Ogura Y (2001)
Cuthbert AP (2002)
Weersma RK (2009)
Vermeire S (2002)
Vind I (2005)
Zaahl MG (2005)
Cavanaugh JA (2003)
Hampe J (2002)
Lakatos PL (2005)
Roussomoustakaki M (2003)
Mendoza JL (2003)
Rodrigo L (2007)
van der Linde K (2007)
Ferreira AC (2005)
Sugimura K (2003)
Murillo L (2002)
Oostenbrug LE (2006)
Protic MB (2007)
Kugathasan S (2005)
Karban A (2005)
Bene J (2006)
Ernst A (2007)
Radlmayr M (2002)
Baptista ML (2008)
Karban A (2004)
Hampe J (2001)
Vermeire S (2004)
Gazouli M (2004)
Karban A (2005)Rigoli L (2008)
Zhou Z (2002)
Magyari L (2009)
Bonen DK (2003)
Diego CD (2006)
Tukel T (2004)
Guo QS (2004)
Kugathasan S (2005)
Ozen SC (2006)
Ferraris A (2006)
Giachino D (2004)
Cukovic-Cavak S (2006)
Annese V (2005)
Nagy Z (2005)
Leung E (2005)
Newman B (2004)
Canto E (2007)
Derakhshan F (2008)
Buhner S (2006)
Cucchiara S (2007)
Cottone M (2006)
Queiroz DM, (2009)
Torkvist L (2006)
Study
Riss L (2007)
Russel RK (2005)
de Ridder L (2007)
Esters N (2004)
Nunez C (2004)
Tukel T (2004)
Ince AT (2008)
Hradsky O (2008)
Vavassori P (2004)
Kugathasan S (2005)
Jess T (2005)
Braat H (2005)
Lappalainen M (2008)
Brant SR (2007)
Bianchi V (2007)
3.84 (3.41, 4.32)
6.50 (3.33, 12.68)
4.17 (1.50, 11.57)6.86 (2.50, 18.83)
3.86 (1.35, 11.03)
5.48 (2.57, 11.67)
7.06 (3.47, 14.37)
5.46 (2.59, 11.49)2.97 (1.42, 6.22)
4.91 (0.25, 95.57)
2.95 (1.13, 7.72)
2.82 (1.75, 4.55)
2.26 (1.03, 4.95)
2.13 (1.31, 3.46)
3.23 (1.72, 6.10)
3.69 (2.73, 4.98)
16.35 (2.24, 119.53)
2.63 (1.10, 6.32)
0.30 (0.04, 2.41)
7.54 (3.48, 16.32)
4.73 (3.26, 6.86)
4.78 (2.48, 9.21)
1.82 (0.30, 11.07)
3.66 (1.78, 7.55)
1.75 (0.49, 6.21)
6.12 (1.81, 20.64)
4.49 (2.18, 9.22)
3.56 (1.87, 6.77)
9.27 (2.74, 31.36)
2.87 (1.71, 4.83)
64.25 (3.92, 1052.26)
2.15 (0.13, 34.64)
5.58 (0.23, 137.89)
5.24 (1.52, 18.07)
5.70 (3.34, 9.74)
9.54 (3.28, 27.77)
4.56 (1.47, 14.08)
3.22 (1.28, 8.08)
4.11 (2.59, 6.54)
6.41 (2.87, 14.31)
3.42 (1.75, 6.69)
3.17 (1.30, 7.73)3.61 (1.46, 8.95)
1.73 (0.82, 3.68)
5.10 (2.18, 11.94)
2.45 (1.53, 3.92)
2.35 (0.96, 5.73)
4.18 (2.09, 8.37)
11.83 (0.72, 194.03)
7.06 (0.43, 115.39)
7.67 (0.37, 161.00)
6.18 (2.08, 18.40)
2.88 (1.27, 6.53)
2.90 (1.30, 6.45)
13.97 (4.35, 44.87)
4.03 (1.40, 11.55)
10.91 (3.30, 36.08)
1.76 (0.95, 3.26)
4.26 (0.53, 34.53)
2.54 (0.35, 18.34)
18.74 (2.53, 138.87)
4.54 (2.23, 9.26)
4.26 (1.82, 9.98)
26.98 (6.62, 109.87)
1.13 (0.35, 3.59)
OR (95% CI)
2.13 (1.15, 3.92)
3.51 (1.00, 12.37)
1.70 (1.02, 2.82)
3.01 (1.55, 5.84)
5.19 (1.49, 18.10)
49.85 (2.29, 1082.74)
1.30 (0.08, 20.99)
4.76 (3.39, 6.69)
10.40 (3.17, 34.13)
6.82 (4.12, 11.29)
1.13 (0.24, 5.23)
2.34 (1.10, 4.98)
3.14 (1.26, 7.78)
2.96 (1.66, 5.30)
5.80 (1.69, 19.89)
1.79
1.021.03
0.97
1.55
1.67
1.581.59
0.15
1.11
2.49
1.47
2.46
1.90
3.31
0.33
1.27
0.30
1.50
2.98
1.83
0.39
1.63
0.72
0.77
1.64
1.87
0.77
2.32
0.17
0.17
0.13
0.75
2.26
0.95
0.87
1.18
2.56
1.43
1.79
1.241.21
1.55
1.32
2.53
1.24
1.72
0.17
0.17
0.15
0.92
1.39
1.44
0.82
0.97
0.79
1.97
0.30
0.33
0.32
1.66
1.32
0.61
0.83
Weight
1.98
0.73
2.38
1.81
0.74
0.14
0.17
3.12
0.80
2.39
0.52
1.55
1.21
2.09
0.75
6.50 (3.33, 12.68)
4.17 (1.50, 11.57)6.86 (2.50, 18.83)
3.86 (1.35, 11.03)
5.48 (2.57, 11.67)
7.06 (3.47, 14.37)
5.46 (2.59, 11.49)2.97 (1.42, 6.22)
4.91 (0.25, 95.57)
2.95 (1.13, 7.72)
2.82 (1.75, 4.55)
2.26 (1.03, 4.95)
2.13 (1.31, 3.46)
3.23 (1.72, 6.10)
3.69 (2.73, 4.98)
16.35 (2.24, 119.53)
2.63 (1.10, 6.32)
0.30 (0.04, 2.41)
7.54 (3.48, 16.32)
4.73 (3.26, 6.86)
4.78 (2.48, 9.21)
1.82 (0.30, 11.07)
3.66 (1.78, 7.55)
1.75 (0.49, 6.21)
6.12 (1.81, 20.64)
4.49 (2.18, 9.22)
3.56 (1.87, 6.77)
9.27 (2.74, 31.36)
2.87 (1.71, 4.83)
64.25 (3.92, 1052.26)
2.15 (0.13, 34.64)
5.58 (0.23, 137.89)
5.24 (1.52, 18.07)
5.70 (3.34, 9.74)
9.54 (3.28, 27.77)
4.56 (1.47, 14.08)
3.22 (1.28, 8.08)
4.11 (2.59, 6.54)
6.41 (2.87, 14.31)
3.42 (1.75, 6.69)
3.17 (1.30, 7.73)3.61 (1.46, 8.95)
1.73 (0.82, 3.68)
5.10 (2.18, 11.94)
2.45 (1.53, 3.92)
2.35 (0.96, 5.73)
4.18 (2.09, 8.37)
11.83 (0.72, 194.03)
7.06 (0.43, 115.39)
7.67 (0.37, 161.00)
6.18 (2.08, 18.40)
2.88 (1.27, 6.53)
2.90 (1.30, 6.45)
13.97 (4.35, 44.87)
4.03 (1.40, 11.55)
10.91 (3.30, 36.08)
1.76 (0.95, 3.26)
4.26 (0.53, 34.53)
2.54 (0.35, 18.34)
18.74 (2.53, 138.87)
4.54 (2.23, 9.26)
4.26 (1.82, 9.98)
26.98 (6.62, 109.87)
1.13 (0.35, 3.59)
OR (95% CI)
2.13 (1.15, 3.92)
3.51 (1.00, 12.37)
1.70 (1.02, 2.82)
3.01 (1.55, 5.84)
5.19 (1.49, 18.10)
49.85 (2.29, 1082.74)
1.30 (0.08, 20.99)
4.76 (3.39, 6.69)
10.40 (3.17, 34.13)
6.82 (4.12, 11.29)
1.13 (0.24, 5.23)
2.34 (1.10, 4.98)
3.14 (1.26, 7.78)
2.96 (1.66, 5.30)
5.80 (1.69, 19.89)
1.79
1.021.03
0.97
1.55
1.67
1.581.59
0.15
1.11
2.49
1.47
2.46
1.90
3.31
0.33
1.27
0.30
1.50
2.98
1.83
0.39
1.63
0.72
0.77
1.64
1.87
0.77
2.32
0.17
0.17
0.13
0.75
2.26
0.95
0.87
1.18
2.56
1.43
1.79
1.241.21
1.55
1.32
2.53
1.24
1.72
0.17
0.17
0.15
0.92
1.39
1.44
0.82
0.97
0.79
1.97
0.30
0.33
0.32
1.66
1.32
0.61
0.83
Weight, %
1.98
0.73
2.38
1.81
0.74
0.14
0.17
3.12
0.80
2.39
0.52
1.55
1.21
2.09
0.75
1.05 1 5 10 50
Crohn’s disease
Odds ratio (95% CI)
3.89 (3.58, 4.24)
Supplementary Figure 5. Detailed meta-analysis of Arg702Trp on the basis of allele frequencies. Ulcerative colitis. All studies..
Random effect
Fixed effect
Annese V (2005)Esters N (2004)
Giachino D (2004)
Weersma RK (2009)
Brant SR (2007)
Helio T (2003)
Oostenbrug LE (2006)
Zaahl MG (2005)
Hugot JP (2001)
de Ridder L (2007)
Bianchi V (2007)
Ozen SC (2006)
Ferraris A (2006)
Ince AT (2008)
Cucchiara S (2007)
Karban A (2004)
Crawford NPS (2007)
Braat H (2005)
Russel RK (2005)Economou M (2007)
Arnot IDR (2004)
Jess T (2005)
Cuthbert AP (2002)
Rigoli L (2008)
Ernst A (2007)
Gearry RB (2007)
van der Linde K (2007)
Buning C (2005)
Gazouli M (2004)
Derakhshan F (2008)
Protic MB (2007)
Cavanaugh JA (2003)
Study
1.10 (0.90, 1.34)
0.97 (0.54, 1.77)1.39 (0.75, 2.54)
1.93 (1.02, 3.67)
1.00 (0.77, 1.29)
1.54 (0.75, 3.16)
0.82 (0.23, 2.98)
0.75 (0.40, 1.41)
0.47 (0.06, 3.96)
0.80 (0.31, 2.07)
3.52 (1.42, 8.74)
0.70 (0.27, 1.85)
OR (95% CI)
0.88 (0.22, 3.57)
2.06 (0.74, 5.78)
0.51 (0.13, 1.95)
1.18 (0.64, 2.20)
2.21 (0.55, 8.97)
2.29 (0.63, 8.31)
2.01 (0.97, 4.16)
0.77 (0.27, 2.22)1.26 (0.38, 4.13)
0.46 (0.23, 0.95)
0.11 (0.01, 2.05)
1.04 (0.60, 1.79)
0.91 (0.17, 4.80)
1.16 (0.75, 1.81)
1.51 (0.80, 2.84)
0.78 (0.23, 2.60)
1.19 (0.47, 2.99)
7.52 (1.66, 34.09)
0.25 (0.03, 2.22)
0.09 (0.02, 0.39)
0.13 (0.01, 2.18)
5.085.01
4.77
7.95
4.24
1.95
4.86
0.82
3.04
3.21
2.97
Weight
1.70
2.71
1.81
4.91
1.70
1.94
4.19
2.622.19
4.29
0.45
5.50
1.28
6.36
4.82
2.14
3.14
1.50
0.77
1.59
0.49
0.97 (0.54, 1.77)1.39 (0.75, 2.54)
1.93 (1.02, 3.67)
1.00 (0.77, 1.29)
1.54 (0.75, 3.16)
0.82 (0.23, 2.98)
0.75 (0.40, 1.41)
0.47 (0.06, 3.96)
0.80 (0.31, 2.07)
3.52 (1.42, 8.74)
0.70 (0.27, 1.85)
0.88 (0.22, 3.57)
2.06 (0.74, 5.78)
0.51 (0.13, 1.95)
1.18 (0.64, 2.20)
2.21 (0.55, 8.97)
2.29 (0.63, 8.31)
2.01 (0.97, 4.16)
0.77 (0.27, 2.22)1.26 (0.38, 4.13)
0.46 (0.23, 0.95)
0.11 (0.01, 2.05)
1.04 (0.60, 1.79)
0.91 (0.17, 4.80)
1.16 (0.75, 1.81)
1.51 (0.80, 2.84)
0.78 (0.23, 2.60)
1.19 (0.47, 2.99)
7.52 (1.66, 34.09)
0.25 (0.03, 2.22)
0.09 (0.02, 0.39)
0.13 (0.01, 2.18)
5.085.01
4.77
7.95
4.24
1.95
4.86
0.82
3.04
3.21
2.97
1.70
2.71
1.81
4.91
1.70
1.94
4.19
2.622.19
4.29
0.45
5.50
1.28
6.36
4.82
2.14
3.14
1.50
0.77
1.59
0.49
1.05 1 5 10 50
Ulcerative colitis
Odds ratio (95% CI)
1.06 (0.93, 1.20)
Supplementary Figure 6. Detailed meta-analysis of Gly908Arg on the basis of allele frequencies. Ulcerative colitis. All studies.
Studies were excluded from meta-analysis if the risk allele/genotype was found neither in cases nor in controls.
Random effect
Fixed effect
Gearry RB (2007)
Russel RK (2005)
Oostenbrug LE (2006)
Rigoli L (2008)
Braat H (2005)
Cuthbert AP (2002)
Arnot IDR (2004)
Ernst A (2007)
Crawford NPS (2007)
Economou M (2007)
de Ridder L (2007)
Annese V (2005)
Cucchiara S (2007)
Gazouli M (2004)
Helio T (2003)
Esters N (2004)
van der Linde K (2007)
Giachino D (2004)
Weersma RK (2009)
Brant SR (2007)
Buning C (2005)
Derakhshan F (2008)Ozen SC (2006)
Cavanaugh JA (2003)
Ferraris A (2006)Ince AT (2008)
Karban A (2004)
Protic MB (2007)
Hugot JP (2001)Jess T (2005)
Bianchi V (2007)
Zaahl MG (2005)
Study
1.10 (0.87, 1.39)
0.94 (0.34, 2.59)
(Excluded)
0.91 (0.44, 1.86)
1.02 (0.31, 3.40)
0.41 (0.17, 0.97)
3.08 (0.90, 10.49)
7.50 (0.96, 58.85)
0.79 (0.35, 1.80)
1.22 (0.30, 4.96)
0.82 (0.43, 1.59)
0.19 (0.01, 3.10)
0.73 (0.33, 1.58)
1.47 (0.72, 2.99)
4.31 (1.80, 10.33)
(Excluded)
1.77 (0.65, 4.85)
0.58 (0.02, 14.49)
1.95 (0.56, 6.82)
1.00 (0.67, 1.50)
2.00 (0.63, 6.38)
1.30 (0.35, 4.90)
OR (95% CI)
1.51 (0.25, 9.12)0.88 (0.12, 6.32)
0.68 (0.04, 11.84)
0.44 (0.05, 3.95)0.69 (0.06, 7.67)
0.62 (0.13, 3.01)
(Excluded)
0.13 (0.01, 2.69)0.20 (0.01, 4.22)
1.80 (0.36, 8.99)
0.94 (0.04, 23.42)
4.27
0.00
7.24
3.23
5.54
3.13
1.22
5.98
2.48
8.12
0.67
6.47
7.34
5.45
0.00
4.36
0.52
3.02
13.69
3.46
2.74
Weight, %
1.571.33
0.65
1.070.90
1.98
0.00
0.570.57
1.92
0.52
0.94 (0.34, 2.59)
(Excluded)
0.91 (0.44, 1.86)
1.02 (0.31, 3.40)
0.41 (0.17, 0.97)
3.08 (0.90, 10.49)
7.50 (0.96, 58.85)
0.79 (0.35, 1.80)
1.22 (0.30, 4.96)
0.82 (0.43, 1.59)
0.19 (0.01, 3.10)
0.73 (0.33, 1.58)
1.47 (0.72, 2.99)
4.31 (1.80, 10.33)
(Excluded)
1.77 (0.65, 4.85)
0.58 (0.02, 14.49)
1.95 (0.56, 6.82)
1.00 (0.67, 1.50)
2.00 (0.63, 6.38)
1.30 (0.35, 4.90)
1.51 (0.25, 9.12)0.88 (0.12, 6.32)
0.68 (0.04, 11.84)
0.44 (0.05, 3.95)0.69 (0.06, 7.67)
0.62 (0.13, 3.01)
(Excluded)
0.13 (0.01, 2.69)0.20 (0.01, 4.22)
1.80 (0.36, 8.99)
0.94 (0.04, 23.42)
4.27
0.00
7.24
3.23
5.54
3.13
1.22
5.98
2.48
8.12
0.67
6.47
7.34
5.45
0.00
4.36
0.52
3.02
13.69
3.46
2.74
1.571.33
0.65
1.070.90
1.98
0.00
0.570.57
1.92
0.52
1.05 1 5 10 50
Ulcerative colitis
Odds ratio (95% CI)
1.10 (0.91, 1.33)
Supplementary Figure 7. Detailed meta-analysis of Leu1007fsincC on the basis of allele frequencies. Ulcerative colitis. All studies.
Studies were excluded from meta-analysis if the risk allele/genotype was found neither in cases nor in controls.
Random effect
Fixed effect
Ince AT (2008)
Cuthbert AP (2002)
Radlmayr M (2002)
Ernst A (2007)
Bianchi V (2007)Rigoli L (2008)van der Linde K (2007)
Buning C (2005)
Karban A (2004)
Braat H (2005)
Hugot JP (2001)
Hampe J (2001)
Oostenbrug LE (2006)
Cucchiara S (2007)
Esters N (2004)Gearry RB (2007)
Ozen SC (2006)
Crawford NPS (2007)
Study Ulcerative colitits
Protic MB (2007)
Helio T (2003)
Zaahl MG (2005)
Cavanaugh JA (2003)
Derakhshan F (2008)Roussomoustakaki M (2003)
de Ridder L (2007)
Weersma RK (2009)
Giachino D (2004)
Jess T (2005)
Russel RK (2005)
Brant SR (2007)
Gazouli M (2004)
Economou M (2007)
Guo QS (2004)
Ferraris A (2006)
Arnot IDR (2004)
Annese V (2005)
1.02 (0.85, 1.24)
0.46 (0.02, 11.31)
0.71 (0.34, 1.51)
1.24 (0.31, 5.03)
0.89 (0.43, 1.84)
2.41 (0.53, 10.88)0.76 (0.15, 3.83)1.18 (0.19, 7.22)
1.09 (0.38, 3.09)
0.36 (0.04, 3.01)
1.06 (0.44, 2.57)
0.48 (0.11, 2.17)
0.69 (0.23, 2.02)
0.66 (0.29, 1.48)
1.72 (0.72, 4.08)
0.47 (0.16, 1.39)1.41 (0.48, 4.20)
(Excluded)
0.98 (0.31, 3.03)
30.76 (1.79, 529.89)
OR (95% CI)
1.84 (0.66, 5.14)
1.07 (0.28, 4.17)
0.68 (0.04, 11.84)
0.20 (0.01, 4.15)0.28 (0.01, 5.91)
0.79 (0.18, 3.45)
1.00 (0.67, 1.50)
0.24 (0.03, 1.90)
0.25 (0.03, 2.25)
0.29 (0.01, 5.59)
1.24 (0.53, 2.89)
0.57 (0.21, 1.56)
1.06 (0.48, 2.32)
4.70 (0.42, 52.22)
2.24 (0.59, 8.44)
2.82 (0.93, 8.56)
3.76 (1.12, 12.63)
0.35
6.05
1.80
6.35
1.561.351.09
3.18
0.79
4.41
1.56
3.01
5.17
4.57
2.962.94
0.00
2.72
0.44
Weight, %
3.30
1.92
0.44
0.390.39
1.63
18.18
0.82
0.73
0.41
4.77
3.45
5.48
0.62
2.00
2.82
2.39
1.02 (0.85, 1.24)
0.46 (0.02, 11.31)
0.71 (0.34, 1.51)
1.24 (0.31, 5.03)
0.89 (0.43, 1.84)
2.41 (0.53, 10.88)0.76 (0.15, 3.83)1.18 (0.19, 7.22)
1.09 (0.38, 3.09)
0.36 (0.04, 3.01)
1.06 (0.44, 2.57)
0.48 (0.11, 2.17)
0.69 (0.23, 2.02)
0.66 (0.29, 1.48)
1.72 (0.72, 4.08)
0.47 (0.16, 1.39)1.41 (0.48, 4.20)
(Excluded)
0.98 (0.31, 3.03)
30.76 (1.79, 529.89)
1.84 (0.66, 5.14)
1.07 (0.28, 4.17)
0.68 (0.04, 11.84)
0.20 (0.01, 4.15)0.28 (0.01, 5.91)
0.79 (0.18, 3.45)
1.00 (0.67, 1.50)
0.24 (0.03, 1.90)
0.25 (0.03, 2.25)
0.29 (0.01, 5.59)
1.24 (0.53, 2.89)
0.57 (0.21, 1.56)
1.06 (0.48, 2.32)
4.70 (0.42, 52.22)
2.24 (0.59, 8.44)
2.82 (0.93, 8.56)
3.76 (1.12, 12.63)
0.35
6.05
1.80
6.35
1.561.351.09
3.18
0.79
4.41
1.56
3.01
5.17
4.57
2.962.94
0.00
2.72
0.44
3.30
1.92
0.44
0.390.39
1.63
18.18
0.82
0.73
0.41
4.77
3.45
5.48
0.62
2.00
2.82
2.39
1.05 1 5 10 50
Odds ratio (95% CI)
1.05 (0.88, 1.25)
Supplementary Figure 8. Detailed meta-analysis of Arg702Trp on the basis of allele frequencies. Crohn’s disease. Northern Europeans.
Random effect
Fixed effect
Ernst A (2007)
Riss L (2007)
Weersma RK (2009)
Oostenbrug LE (2006)
Hampe J (2002)
Vermeire S (2004)
Cuthbert AP (2002)
Lappalainen M (2008)
Ahmad T (2002)
Arnot IDR (2004)
Helio T (2003)
Braat H (2005)
Russel RK (2005)
Study Crohn’s disease
Vind I (2005)
Jess T (2005)
Buhner S (2006)
van der Linde K (2007)
Esters N (2004)
de Ridder L (2007)
Torkvist L (2006)
2.17 (1.88, 2.49)
2.02 (1.32, 3.09)
OR (95% CI)
1.93 (1.11, 3.36)
1.65 (1.33, 2.04)
1.88 (1.21, 2.92)
2.72 (1.92, 3.84)
2.94 (1.74, 4.96)
2.72 (1.64, 4.50)
2.15 (0.83, 5.55)
2.63 (1.71, 4.04)
1.48 (0.88, 2.51)
1.84 (0.86, 3.93)
2.89 (1.47, 5.65)
1.19 (0.58, 2.43)
0.23 (0.01, 4.59)
3.76 (1.11, 12.80)
3.15 (1.06, 9.32)
1.53 (0.68, 3.45)
2.42 (1.48, 3.97)
2.96 (1.77, 4.93)
6.68 (1.52, 29.31)
7.48
Weight
5.08
15.58
7.22
9.84
5.57
5.87
2.01
7.42
5.53
3.00
3.70
3.35
0.22
1.25
1.57
2.64
6.05
5.75
0.87
2.17 (1.88, 2.49)
2.02 (1.32, 3.09)
OR (95% CI)
1.93 (1.11, 3.36)
1.65 (1.33, 2.04)
1.88 (1.21, 2.92)
2.72 (1.92, 3.84)
2.94 (1.74, 4.96)
2.72 (1.64, 4.50)
2.15 (0.83, 5.55)
2.63 (1.71, 4.04)
1.48 (0.88, 2.51)
1.84 (0.86, 3.93)
2.89 (1.47, 5.65)
1.19 (0.58, 2.43)
0.23 (0.01, 4.59)
3.76 (1.11, 12.80)
3.15 (1.06, 9.32)
1.53 (0.68, 3.45)
2.42 (1.48, 3.97)
2.96 (1.77, 4.93)
6.68 (1.52, 29.31)
7.48
Weight, %
5.08
15.58
7.22
9.84
5.57
5.87
2.01
7.42
5.53
3.00
3.70
3.35
0.22
1.25
1.57
2.64
6.05
5.75
0.87
1.05 1 5 10 50
Odds ratio (95% CI)
2.12 (1.90, 2.37)
Supplementary Figure 9. Detailed meta-analysis of Gly908Arg on the asis of allele frequencies. Crohn’s disease. Northern Europeans.
Random effectt
Fixed effect
Torkvist L (2006)
Arnot IDR (2004)
Weersma RK (2009)
Oostenbrug LE (2006)
Cuthbert AP (2002)
Hampe J (2002)
Ernst A (2007)
de Ridder L (2007)
Ahmad T (2002)
Vermeire S (2004)
Study
van der Linde K (2007)
Riss L (2007)
Vind I (2005)
Jess T (2005)
Lappalainen M (2008)
Braat H (2005)
Esters N (2004)
Russel RK (2005)
Buhner S (2006)
Helio T (2003)
2.30 (1.72, 3.08)
12.30 (0.70, 216.21)
7.10 (0.93, 54.19)
2.05 (1.49, 2.82)
OR (95% CI)
1.42 (0.83, 2.45)
6.71 (2.03, 22.14)
5.72 (2.91, 11.25)
1.55 (0.73, 3.29)
1.31 (0.78, 2.22)
2.33 (1.05, 5.18)
2.10 (0.81, 5.42)
9.88 (1.29, 75.93)
0.99 (0.35, 2.81)
4.32 (0.83, 22.66)
2.31 (0.38, 14.24)
3.98 (0.19, 83.06)
1.11 (0.59, 2.09)
3.43 (1.47, 7.97)
11.20 (0.64, 197.01)
2.63 (0.57, 12.19)
7.79 (0.40, 151.18)
0.96
1.79
12.56
Weight
9.75
4.22
8.21
7.41
9.99
6.98
5.72
1.78
5.10
2.54
2.17
0.86
8.65
6.57
0.96
2.88
0.90
2.30 (1.72, 3.08)
12.30 (0.70, 216.21)
7.10 (0.93, 54.19)
2.05 (1.49, 2.82)
OR (95% CI)
1.42 (0.83, 2.45)
6.71 (2.03, 22.14)
5.72 (2.91, 11.25)
1.55 (0.73, 3.29)
1.31 (0.78, 2.22)
2.33 (1.05, 5.18)
2.10 (0.81, 5.42)
9.88 (1.29, 75.93)
0.99 (0.35, 2.81)
4.32 (0.83, 22.66)
2.31 (0.38, 14.24)
3.98 (0.19, 83.06)
1.11 (0.59, 2.09)
3.43 (1.47, 7.97)
11.20 (0.64, 197.01)
2.63 (0.57, 12.19)
7.79 (0.40, 151.18)
0.96
1.79
12.56
Weight, %
9.75
4.22
8.21
7.41
9.99
6.98
5.72
1.78
5.10
2.54
2.17
0.86
8.65
6.57
0.96
2.88
0.90
1.05 1 5 10 50
Crohn’s disease
Odds ratio (95% CI)
2.25 (1.89, 2.68)
Supplementary Figure 10. Detailed meta-analysis of Leu1007fsincC on the basis of allele frequencies. Crohn’s disease. Northern Europeans.
Random effect
Fixed effect
Vind I (2005)
Hampe J (2001)
Oostenbrug LE (2006)
Vermeire S (2004)
Helio T (2003)
Lappalainen M (2008)
Buhner S (2006)
Murillo L (2002)
Russel RK (2005)
Jess T (2005)
Radlmayr M (2002)
Riss L (2007)
Ernst A (2007)
Braat H (2005)
Study
Cuthbert AP (2002)
Arnot IDR (2004)
Hampe J (2002)
Esters N (2004)
Torkvist L (2006)
van der Linde K (2007)
de Ridder L (2007)
Ahmad T (2002)
Weersma RK (2009)3.65 (2.98, 4.47)
4.98 (1.55, 16.02)
4.11 (2.59, 6.54)
2.87 (1.71, 4.83)
6.41 (2.87, 14.31)
2.97 (1.42, 6.22)
3.14 (1.26, 7.78)
18.74 (2.53, 138.87)
9.27 (2.74, 31.36)
3.51 (1.00, 12.37)
1.13 (0.24, 5.23)
9.54 (3.28, 27.77)
1.75 (0.78, 3.94)
5.70 (3.34, 9.74)
2.34 (1.10, 4.98)
OR (95% CI)
3.23 (1.72, 6.10)
3.86 (1.35, 11.03)
4.73 (3.26, 6.86)
3.01 (1.55, 5.84)
1.13 (0.35, 3.59)
6.12 (1.81, 20.64)
1.70 (1.02, 2.82)
6.50 (3.33, 12.68)
3.69 (2.73, 4.98)
2.38
7.19
6.56
4.09
4.55
3.47
0.94
2.23
2.12
1.52
2.74
4.04
6.38
4.43
Weight
5.41
2.81
8.31
5.16
2.42
2.24
6.71
5.11
9.203.65 (2.98, 4.47)
4.98 (1.55, 16.02)
4.11 (2.59, 6.54)
2.87 (1.71, 4.83)
6.41 (2.87, 14.31)
2.97 (1.42, 6.22)
3.14 (1.26, 7.78)
18.74 (2.53, 138.87)
9.27 (2.74, 31.36)
3.51 (1.00, 12.37)
1.13 (0.24, 5.23)
9.54 (3.28, 27.77)
1.75 (0.78, 3.94)
5.70 (3.34, 9.74)
2.34 (1.10, 4.98)
OR (95% CI)
3.23 (1.72, 6.10)
3.86 (1.35, 11.03)
4.73 (3.26, 6.86)
3.01 (1.55, 5.84)
1.13 (0.35, 3.59)
6.12 (1.81, 20.64)
1.70 (1.02, 2.82)
6.50 (3.33, 12.68)
3.69 (2.73, 4.98)
2.38
7.19
6.56
4.09
4.55
3.47
0.94
2.23
2.12
1.52
2.74
4.04
6.38
4.43
Weight, %
5.41
2.81
8.31
5.16
2.42
2.24
6.71
5.11
9.20
1.05 1 5 10 50
Crohn’s disease
Odds ratio (95% CI)
3.78 (3.30, 4.32)
Supplementary Figure 11. Detailed meta-analysis of Arg702Trp on the basis of allele frequencies. Crohn’s disease. Southern Europeans.
Random effect
Fixed effect
Protic MB (2007)
Karban A (2004)
Ferraris A (2006)
Lakatos PL (2005)
Nagy Z (2005)
Hradsky O (2008)
Vind I (2005)
Giachino D (2004)
Economou M (2007)
Cottone M (2006)
Bianchi V (2007)Nunez C (2004)
Mendoza JL (2003)
Riss L (2007)
Heresbach D (2004)
Study
Vavassori P (2004)
Ferreira AC (2005)
Buning C (2005)
Bene J (2006)
Rodrigo L (2007)
Annese V (2005)
Rigoli L (2008)
Cucchiara S (2007)
Karban A (2005)
Diego CD (2006)
Gazouli M (2004)
Magyari L (2009)
Canto E (2007)
Cukovic-Cavak S (2006)
2.34 (1.98, 2.78)
1.50 (0.90, 2.50)
4.13 (1.38, 12.34)
4.51 (1.91, 10.64)
2.55 (1.37, 4.73)
2.30 (1.00, 5.27)
1.48 (0.95, 2.30)
2.04 (0.77, 5.37)
1.56 (0.89, 2.76)
3.85 (1.25, 11.93)
2.98 (1.33, 6.70)
1.79 (0.94, 3.42)1.17 (0.62, 2.20)
3.52 (1.70, 7.26)
2.99 (1.50, 5.97)
2.60 (1.25, 5.43)
1.52 (0.28, 8.37)
OR (95% CI)
3.31 (2.03, 5.38)
2.81 (1.33, 5.92)
1.89 (0.58, 6.10)
0.79 (0.36, 1.72)
2.20 (1.26, 3.85)
4.36 (1.64, 11.55)
3.01 (1.83, 4.95)
4.24 (1.46, 12.30)
2.29 (1.15, 4.58)
11.00 (2.57, 47.14)
1.41 (0.66, 3.03)
6.59 (1.52, 28.55)
2.79 (1.35, 5.76)
5.47
1.99
2.90
4.46
3.04
6.29
2.41
4.92
1.89
3.15
4.244.34
3.66
3.90
3.60
0.92
Weight,%
5.75
3.53
1.77
3.31
5.00
2.39
5.62
2.08
3.88
1.22
3.42
1.20
3.67
2.34 (1.98, 2.78)
1.50 (0.90, 2.50)
4.13 (1.38, 12.34)
4.51 (1.91, 10.64)
2.55 (1.37, 4.73)
2.30 (1.00, 5.27)
1.48 (0.95, 2.30)
2.04 (0.77, 5.37)
1.56 (0.89, 2.76)
3.85 (1.25, 11.93)
2.98 (1.33, 6.70)
1.79 (0.94, 3.42)1.17 (0.62, 2.20)
3.52 (1.70, 7.26)
2.99 (1.50, 5.97)
2.60 (1.25, 5.43)
1.52 (0.28, 8.37)
OR (95% CI)
3.31 (2.03, 5.38)
2.81 (1.33, 5.92)
1.89 (0.58, 6.10)
0.79 (0.36, 1.72)
2.20 (1.26, 3.85)
4.36 (1.64, 11.55)
3.01 (1.83, 4.95)
4.24 (1.46, 12.30)
2.29 (1.15, 4.58)
11.00 (2.57, 47.14)
1.41 (0.66, 3.03)
6.59 (1.52, 28.55)
2.79 (1.35, 5.76)
5.47
1.99
2.90
4.46
3.04
6.29
2.41
4.92
1.89
3.15
4.244.34
3.66
3.90
3.60
0.92
5.75
3.53
1.77
3.31
5.00
2.39
5.62
2.08
3.88
1.22
3.42
1.20
3.67
1.05 1 5 10 50
Odds ratio (95% CI)
Crohn’s disease
2.36 (2.07, 2.68)
Supplementary Figure 12. Detailed meta-analysis of Gly908Arg on the basis of allele frequencies. Crohn’s disease. Southern Europeans.
Odds ratio (95% CI)
Crohn’s disease
Random effect
Fixed effect
Riss L (2007)
Cottone M (2006)Ferreira AC (2005)
Nunez C (2004)
Rodrigo L (2007)
Bene J (2006)
Vavassori P (2004)
Nagy Z (2005)
Karban A (2004)
Cucchiara S (2007)Hradsky O (2008)
Buning C (2005)
Lakatos PL (2005)
Economou M (2007)
Protic MB (2007)
Study
Karban A (2005)
Diego CD (2006)
Mendoza JL (2003)
Heresbach D (2004)
Rigoli L (2008)
Cukovic-Cavak S (2006)
Vind I (2005)
Giachino D (2004)
Bianchi V (2007)
Gazouli M (2004)
Ferraris A (2006)
Annese V (2005)
Canto E (2007)
Magyari L (2009)
3.03 (2.42, 3.80)
1.68 (0.43, 6.58)
4.01 (1.61, 9.99)2.19 (0.90, 5.33)
5.19 (1.49, 18.10)
1.20 (0.24, 5.99)
OR (95% CI)
6.28 (0.78, 50.38)
2.66 (0.97, 7.31)
1.95 (0.43, 8.86)
7.00 (3.12, 15.69)
2.97 (1.63, 5.42)2.82 (1.55, 5.12)
2.58 (0.85, 7.77)
1.76 (0.77, 4.02)
0.84 (0.39, 1.79)
20.60 (1.22, 347.57)
5.76 (2.59, 12.81)
2.63 (0.83, 8.35)
4.64 (1.62, 13.25)
2.37 (0.68, 8.28)
1.03 (0.43, 2.50)
4.15 (0.92, 18.78)
3.69 (0.72, 18.80)
3.17 (1.15, 8.76)
4.79 (1.37, 16.71)
4.55 (1.97, 10.51)
6.89 (2.33, 20.32)
2.85 (1.46, 5.56)
5.83 (0.32, 106.57)
8.20 (1.83, 36.73)2.28
4.224.38
2.64
1.72
Weight
1.08
3.65
1.92
4.97
6.936.99
3.21
4.83
5.36
0.61
5.04
2.99
3.46
2.63
4.42
1.93
1.69
3.63
2.64
4.75
3.30
6.20
0.58
1.95
3.03 (2.42, 3.80)
1.68 (0.43, 6.58)
4.01 (1.61, 9.99)2.19 (0.90, 5.33)
5.19 (1.49, 18.10)
1.20 (0.24, 5.99)
OR (95% CI)
6.28 (0.78, 50.38)
2.66 (0.97, 7.31)
1.95 (0.43, 8.86)
7.00 (3.12, 15.69)
2.97 (1.63, 5.42)2.82 (1.55, 5.12)
2.58 (0.85, 7.77)
1.76 (0.77, 4.02)
0.84 (0.39, 1.79)
20.60 (1.22, 347.57)
5.76 (2.59, 12.81)
2.63 (0.83, 8.35)
4.64 (1.62, 13.25)
2.37 (0.68, 8.28)
1.03 (0.43, 2.50)
4.15 (0.92, 18.78)
3.69 (0.72, 18.80)
3.17 (1.15, 8.76)
4.79 (1.37, 16.71)
4.55 (1.97, 10.51)
6.89 (2.33, 20.32)
2.85 (1.46, 5.56)
5.83 (0.32, 106.57)
8.20 (1.83, 36.73)2.28
4.224.38
2.64
1.72
Weight,%
1.08
3.65
1.92
4.97
6.936.99
3.21
4.83
5.36
0.61
5.04
2.99
3.46
2.63
4.42
1.93
1.69
3.63
2.64
4.75
3.30
6.20
0.58
1.95
1.05 1 5 10 50
3.20 (2.67, 3.83)
Supplementary Figure 13. Detailed meta-analysis of Leu1007fsincC on the basis of allele frequencies. Crohn’s disease. Southern Europeans.
Random effect
Fixed effect
Cukovic-Cavak S (2006)
Ferraris A (2006)
Rodrigo L (2007)
Cottone M (2006)
Ferreira AC (2005)
Protic MB (2007)
Roussomoustakaki M (2003)
Mendoza JL (2003)
Lakatos PL (2005)
Karban A (2005)
Cucchiara S (2007)
Rigoli L (2008)
Magyari L (2009)Giachino D (2004)
Diego CD (2006)
Buning C (2005)
Gazouli M (2004)
Nunez C (2004)
Riss L (2007)
Vind I (2005)
Economou M (2007)
Vavassori P (2004)Bianchi V (2007)Bene J (2006)
Karban A (2004)
Hradsky O (2008)
Nagy Z (2005)
Canto E (2007)
Annese V (2005)
Study
Heresbach D (2004)
4.21 (3.61, 4.91)
2.90 (1.30, 6.45)
6.18 (2.08, 18.40)
1.75 (0.49, 6.21)
4.26 (1.82, 9.98)
4.49 (2.18, 9.22)
64.25 (3.92, 1052.26)
1.82 (0.30, 11.07)
3.66 (1.78, 7.55)
4.78 (2.48, 9.21)
3.17 (1.30, 7.73)
4.54 (2.23, 9.26)
OR (95% CI)
3.61 (1.46, 8.95)
5.10 (2.18, 11.94)2.88 (1.27, 6.53)
2.35 (0.96, 5.73)
5.48 (2.57, 11.67)
3.42 (1.75, 6.69)
5.19 (1.49, 18.10)
2.94 (1.16, 7.45)
0.26 (0.01, 4.75)
7.06 (3.47, 14.37)
10.40 (3.17, 34.13)5.80 (1.69, 19.89)5.24 (1.52, 18.07)
3.22 (1.28, 8.08)
4.76 (3.39, 6.69)
4.03 (1.40, 11.55)
4.26 (0.53, 34.53)
13.97 (4.35, 44.87)
2.26 (1.03, 4.95)3.66
1.97
1.45
3.23
4.50
0.30
0.72
4.47
5.42
2.93
4.61
Weight
2.84
3.233.49
2.93
4.10
5.20
1.50
2.70
0.28
4.62
1.651.541.52
2.76
20.22
2.11
0.53
1.72
3.80
4.21 (3.61, 4.91)
2.90 (1.30, 6.45)
6.18 (2.08, 18.40)
1.75 (0.49, 6.21)
4.26 (1.82, 9.98)
4.49 (2.18, 9.22)
64.25 (3.92, 1052.26)
1.82 (0.30, 11.07)
3.66 (1.78, 7.55)
4.78 (2.48, 9.21)
3.17 (1.30, 7.73)
4.54 (2.23, 9.26)
OR (95% CI)
3.61 (1.46, 8.95)
5.10 (2.18, 11.94)2.88 (1.27, 6.53)
2.35 (0.96, 5.73)
5.48 (2.57, 11.67)
3.42 (1.75, 6.69)
5.19 (1.49, 18.10)
2.94 (1.16, 7.45)
0.26 (0.01, 4.75)
7.06 (3.47, 14.37)
10.40 (3.17, 34.13)5.80 (1.69, 19.89)5.24 (1.52, 18.07)
3.22 (1.28, 8.08)
4.76 (3.39, 6.69)
4.03 (1.40, 11.55)
4.26 (0.53, 34.53)
13.97 (4.35, 44.87)
2.26 (1.03, 4.95)3.66
1.97
1.45
3.23
4.50
0.30
0.72
4.47
5.42
2.93
4.61
Weight, %
2.84
3.233.49
2.93
4.10
5.20
1.50
2.70
0.28
4.62
1.651.541.52
2.76
20.22
2.11
0.53
1.72
3.80
1.05 1 5 10 50
Odds ratio (95% CI)
Crohn’s disease
4.45 (3.82, 5.18)
Supplementary Figure 14. Detailed meta-analysis of Arg702Trp on the basis of allele frequencies. Crohn’s disease. Adults.
Odds ratio (95% CI)
Crohn’s disease
Random effect
Fixed effect
Annese V (2005)
Karban A (2004)
Diego CD (2006)
Bene J (2006)
Buning C (2005)
Study
Riss L (2007)
Arnot IDR (2004)
Lakatos PL (2005)
de Ridder L (2008)
Brant SR (2007)
Nagy Z (2005)
Torkvist L (2006)
Magyari L (2009)
2.43 (2.03, 2.91)
OR (95% CI)
2.20 (1.26, 3.85)
4.13 (1.38, 12.34)
2.29 (1.15, 4.58)
2.35 (0.71, 7.75)
2.81 (1.33, 5.92)
2.31 (1.50, 3.57)
1.48 (0.88, 2.51)
2.55 (1.37, 4.73)
2.86 (1.69, 4.82)
3.49 (2.08, 5.86)
2.30 (1.00, 5.27)
6.68 (1.52, 29.31)
1.50 (0.63, 3.55)
Weight
10.40
2.71
6.76
2.28
5.84
17.27
11.80
8.46
11.82
12.10
4.72
1.49
4.37
2.43 (2.03, 2.91)
OR (95% CI)
2.20 (1.26, 3.85)
4.13 (1.38, 12.34)
2.29 (1.15, 4.58)
2.35 (0.71, 7.75)
2.81 (1.33, 5.92)
2.31 (1.50, 3.57)
1.48 (0.88, 2.51)
2.55 (1.37, 4.73)
2.86 (1.69, 4.82)
3.49 (2.08, 5.86)
2.30 (1.00, 5.27)
6.68 (1.52, 29.31)
1.50 (0.63, 3.55)
Weight, %
10.40
2.71
6.76
2.28
5.84
17.27
11.80
8.46
11.82
12.10
4.72
1.49
4.37
1.05 1 5 10 50
2.46 (2.06, 2.95)
Supplementary Figure 15. Detailed meta-analysis of Gly908Arg on the basis of allele frequencies. Crohn’s disease. Adults.
Random effect
Fixed effect
Arnot IDR (2004)
Nagy Z (2005)
Bene J (2006)
Buning C (2005)
Brant SR (2007)
Karban A (2004)
Lakatos PL (2005)
de Ridder L (2008)
Diego CD (2006)
Riss L (2007)
Torkvist L (2006)
Magyari L (2009)
Annese V (2005)
Study
2.59 (1.79, 3.75)
7.10 (0.93, 54.19)
1.95 (0.43, 8.86)
1.80 (0.16, 20.12)
2.58 (0.85, 7.77)
4.06 (1.69, 9.73)
7.00 (3.12, 15.69)
1.76 (0.77, 4.02)
1.37 (0.80, 2.35)
2.63 (0.83, 8.35)
1.21 (0.53, 2.76)
12.30 (0.70, 216.21)
5.78 (0.69, 48.50)
OR (95% CI)
2.85 (1.46, 5.56)
2.90
4.76
2.13
7.57
10.09
11.01
10.75
15.55
7.12
10.73
1.55
2.68
Weight
13.16
2.59 (1.79, 3.75)
7.10 (0.93, 54.19)
1.95 (0.43, 8.86)
1.80 (0.16, 20.12)
2.58 (0.85, 7.77)
4.06 (1.69, 9.73)
7.00 (3.12, 15.69)
1.76 (0.77, 4.02)
1.37 (0.80, 2.35)
2.63 (0.83, 8.35)
1.21 (0.53, 2.76)
12.30 (0.70, 216.21)
5.78 (0.69, 48.50)
OR (95% CI)
2.85 (1.46, 5.56)
2.90
4.76
2.13
7.57
10.09
11.01
10.75
15.55
7.12
10.73
1.55
2.68
Weight, %
13.16
1.05 1 5 10 50
Odds ratio (95% CI)
Crohn’s disease
2.61 (2.02, 3.37)
Supplementary Figure 16. Detailed meta-analysis of Leu1007fsincC on the basis of allele frequencies. Crohn’s disease. Adults.
Odds ratio (95% CI)
Crohn’s disease
Random effect
Fixed effect
de Ridder L (2008)
Bene J (2006)
Lakatos PL (2005)
Karban A (2004)
Annese V (2005)
Nagy Z (2005)
Buning C (2005)
Diego CD (2006)
Arnot IDR (2004)
Study
Magyari L (2009)
Torkvist L (2006)
Riss L (2007)
Brant SR (2007)
3.25 (2.36, 4.49)
1.61 (0.95, 2.71)
4.24 (1.17, 15.37)
4.78 (2.48, 9.21)
3.22 (1.28, 8.08)
13.97 (4.35, 44.87)
4.03 (1.40, 11.55)
5.48 (2.57, 11.67)
2.35 (0.96, 5.73)
3.86 (1.35, 11.03)
OR (95% CI)
4.83 (1.61, 14.47)
1.13 (0.35, 3.59)
2.13 (1.15, 3.92)
2.96 (1.66, 5.30)
11.81
4.60
10.03
7.16
5.29
6.06
8.84
7.41
6.08
Weight
5.75
5.34
10.62
11.02
3.25 (2.36, 4.49)
1.61 (0.95, 2.71)
4.24 (1.17, 15.37)
4.78 (2.48, 9.21)
3.22 (1.28, 8.08)
13.97 (4.35, 44.87)
4.03 (1.40, 11.55)
5.48 (2.57, 11.67)
2.35 (0.96, 5.73)
3.86 (1.35, 11.03)
OR (95% CI)
4.83 (1.61, 14.47)
1.13 (0.35, 3.59)
2.13 (1.15, 3.92)
2.96 (1.66, 5.30)
11.81
4.60
10.03
7.16
5.29
6.06
8.84
7.41
6.08
Weight, %
5.75
5.34
10.62
11.02
1.05 1 5 10 50
3.35 (2.70, 4.16)
Supplementary Figure 17. Detailed meta-analysis of Arg702Trp on the basis of allele frequencies. Crohn’s disease. Children.
Odds ratio (95% CI)
Crohn’s disease
Random effect
Fixed effect
Study
Kugathasan S (2005)
Cucchiara S (2007)
Russel RK (2005)
Magyari L (2009)
Bene J (2006)
Tomer G (2003)
de Ridder L (2007)
Ferraris A (2006)
Kugathasan S (2005)
Kugathasan S (2005)
2.17 (1.19, 3.95)
OR (95% CI)
1.26 (0.76, 2.07)
3.01 (1.83, 4.95)
1.19 (0.58, 2.43)
0.64 (0.07, 5.87)
0.64 (0.07, 5.87)
5.47 (1.48, 20.16)
7.89 (4.32, 14.43)
4.51 (1.91, 10.64)
0.44 (0.02, 7.89)
0.53 (0.06, 4.80)
Weight
15.28
15.29
13.78
5.12
5.12
9.47
14.58
12.68
3.47
5.19
2.17 (1.19, 3.95)
OR (95% CI)
1.26 (0.76, 2.07)
3.01 (1.83, 4.95)
1.19 (0.58, 2.43)
0.64 (0.07, 5.87)
0.64 (0.07, 5.87)
5.47 (1.48, 20.16)
7.89 (4.32, 14.43)
4.51 (1.91, 10.64)
0.44 (0.02, 7.89)
0.53 (0.06, 4.80)
Weight, %
15.28
15.29
13.78
5.12
5.12
9.47
14.58
12.68
3.47
5.19
1.05 1 5 10 50
2.41 (1.89, 3.06)
Supplementary Figure 18. Detailed meta-analysis of Gly908Arg on the basis of allele frequencies. Crohn’s disease. Children.
Studies were excluded from meta-analysis if the risk allele/genotype was found neither in cases nor in controls.
Odds ratio (95% CI)
Crohn’s disease
Random effect
Fixed effect
Cucchiara S (2007)
Russel RK (2005)
Magyari L (2009)
Bene J (2006)
Study
Tomer G (2003)
Kugathasan S (2005)
Kugathasan S (2005)
Kugathasan S (2005)
de Ridder L (2007)
Ferraris A (2006)
3.52 (2.01, 6.16)
2.97 (1.63, 5.42)
11.20 (0.64, 197.01)
21.90 (2.59, 185.04)
21.90 (2.59, 185.04)
OR (95% CI)
1.96 (0.98, 3.93)
4.27 (2.23, 8.17)
0.96 (0.05, 18.98)
(Excluded)
1.03 (0.41, 2.59)
6.89 (2.33, 20.32)
19.10
5.38
5.38
Weight, %
17.80
18.43
3.08
0.00
14.73
12.80
3.52 (2.01, 6.16)
2.97 (1.63, 5.42)
11.20 (0.64, 197.01)
21.90 (2.59, 185.04)
21.90 (2.59, 185.04)
OR (95% CI)
1.96 (0.98, 3.93)
4.27 (2.23, 8.17)
0.96 (0.05, 18.98)
(Excluded)
1.03 (0.41, 2.59)
6.89 (2.33, 20.32)
19.10
3.30
5.38
5.38
17.80
18.43
0.00
14.73
12.80
1.05 1 5 10 50
3.29 (2.43, 4.43)
Supplementary Figure 19. Detailed meta-analysis of Leu1007fsincC on the basis of allele frequencies. Crohn’s disease. Children.
Odds ratio (95% CI)
Crohn’s disease
Random effect
Fixed effect
Kugathasan S (2005)
Russel RK (2005)
de Ridder L (2007)
Cucchiara S (2007)
Tomer G (2003)
Kugathasan S (2005)
Bene J (2006)
Magyari L (2009)
Study
Ferraris A (2006)
Kugathasan S (2005)
5.06 (3.81, 6.71)
6.82 (4.12, 11.29)
3.51 (1.00, 12.37)
2.35 (1.16, 4.80)
4.54 (2.23, 9.26)
5.46 (2.59, 11.49)
7.06 (0.43, 115.39)
8.44 (2.11, 33.87)
8.44 (2.11, 33.87)
OR (95% CI)
6.18 (2.08, 18.40)
2.15 (0.13, 34.64)
31.63
5.07
15.84
15.82
14.50
1.03
4.16
4.16
Weight
6.75
1.04
5.06 (3.81, 6.71)
6.82 (4.12, 11.29)
3.51 (1.00, 12.37)
2.35 (1.16, 4.80)
4.54 (2.23, 9.26)
5.46 (2.59, 11.49)
7.06 (0.43, 115.39)
8.44 (2.11, 33.87)
8.44 (2.11, 33.87)
OR (95% CI)
6.18 (2.08, 18.40)
2.15 (0.13, 34.64)
31.63
5.07
15.84
15.82
14.50
1.03
4.16
4.16
Weight, %
6.75
1.04
1.05 1 5 10 50
5.05 (3.80, 6.69)
Esters N (2004)
Hugot JP (2001)
Sugimura K (2003)
Vermeire S (2004)
Annese V (2005)
Helio T (2003)
Study
Tukel T (2004)
Zhou Z (2002)
Jess T (2005)
Tukel T (2004)
Vermeire S (2002)
2. 18 (1.59, 2.97)
1.19 (0.86, 1.63)
3.06 (1.47, 6.39)
1.73 (1.10, 2.73)
2.94 (1.74, 4.96)
2.92 (1.60, 5.32)
1.80 (0.49, 6.60)
6.71 (1.04, 43.16)
1.32 (0.61, 2.88)
3.76 (1.11, 12.80)
1.80 (0.63, 5.11)
3.71 (1.49, 9.24)
14.94
7.90
12.31
11.09
9.82
3.56
%
1.92
7.39
3.91
4.98
6.02
1.19 (0.86, 1.63)
3.06 (1.47, 6.39)
1.73 (1.10, 2.73)
2.94 (1.74, 4.96)
2.92 (1.60, 5.32)
1.80 (0.49, 6.60)
6.71 (1.04, 43.16)
OR (95% CI)
1.32 (0.61, 2.88)
3.76 (1.11, 12.80)
1.80 (0.63, 5.11)
3.71 (1.49, 9.24)
14.94
7.90
12.31
11.09
9.82
3.56
1.92
Weight,
7.39
3.91
4.98
6.02
1.05 1 5 10
Crohn’s disease
Supplementary Figure 20. Detailed meta-analysis of Arg702Trp on the basis of allele frequencies. Crohn’s disease. Familial cases.
1.92 (1.59, 2.31)
Random effect
Fixed effect
Odds ratio (95% CI)
Sugimura K (2003)Zhou Z (2002)
Tukel T (2004)
Helio T (2003)
Study
Hugot JP (2001)
Vermeire S (2002)
Tukel T (2004)
Jess T (2005)
Esters N (2004)
Vermeire S (2004)Annese V (2005)
2.47 (1.86, 3.28)
1.58 (0.95, 2.63)2.53 (1.30, 4.91)
OR (95% CI)
7.52 (1.90, 29.85)
19.69 (0.80, 486.97)
6.49 (1.57, 26.82)
7.75 (0.98, 61.23)
3.19 (1.55, 6.58)
2.31 (0.38, 14.24)
1.87 (1.12, 3.10)
2.10 (0.81, 5.42)2.75 (1.31, 5.76)
18.2812.26
Weight,
3.35
0.65
%
3.17
1.53
10.67
1.97
18.35
6.6510.27
1.58 (0.95, 2.63)2.53 (1.30, 4.91)
7.52 (1.90, 29.85)6.49 (1.57, 26.82)
7.75 (0.98, 61.23)
3.19 (1.55, 6.58)
2.31 (0.38, 14.24)
1.87 (1.12, 3.10)
2.10 (0.81, 5.42)2.75 (1.31, 5.76)
18.2812.26
3.35
0.65
3.17
1.53
10.67
1.97
18.35
6.6510.27
1.05 1 5 10 50
Crohn’s disease
Supplementary Figure 21. Detailed meta-analysis of Gly908Arg on the basis of allele frequencies. Crohn’s disease. Familial cases.
2.41 (1.88, 3.09)
Random effect
Fixed effect
Odds ratio (95% CI)
Hugot JP (2001)Helio T (2003)
Tukel T (2004)
Vermeire S (2002)
Ogura Y (2001)
Zhou Z (2002)Vermeire S (2004)
Sugimura K (2003)
Jess T (2005)
Esters N (2004)
Annese V (2005)
Tukel T (2004)
Study
4.17 (2.64, 6.60)
6.86 (2.50, 18.83)7.20 (2.91, 17.81)
6.06 (2.89, 12.72)
OR (95% CI)
11.95 (1.56, 91.56)
2.13 (1.31, 3.46)
2.21 (0.98, 4.97)6.41 (2.87, 14.31)
3.56 (1.87, 6.77)
1.13 (0.24, 5.23)
1.64 (1.10, 2.45)
14.97 (4.53, 49.43)
49.85 (2.29, 1082.74)
6.997.51
8.36
Weight, %
3.35
9.62
8.008.04
8.86
4.78
9.97
6.12
1.77
6.86 (2.50, 18.83)7.20 (2.91, 17.81)
6.06 (2.89, 12.72)
11.95 (1.56, 91.56)
2.13 (1.31, 3.46)
2.21 (0.98, 4.97)6.41 (2.87, 14.31)
3.56 (1.87, 6.77)
1.13 (0.24, 5.23)
1.64 (1.10, 2.45)
14.97 (4.53, 49.43)
49.85 (2.29, 1082.74)
6.997.51
8.36
3.35
9.62
8.008.04
8.86
4.78
9.97
6.12
1.77
1.05 1 5 10
Supplementary Figure 22. Detailed meta-analysis of Leu1007fsincC on the basis of allele frequencies. Crohn’s disease. Familial cases.
Crohn’s disease
3.28 (2.65, 4.05)
Random effect
Fixed effect
Odds ratio (95% CI)
Cottone M (2006)
Vermeire S (2002)
Cuthbert AP (2002)
Esters N (2004)
Buhner S (2006)
Zhou Z (2002)
Tukel T (2004)
Study
Annese V (2005)
Helio T (2003)
Kugathasan S (2005)
1.87 (1.35, 2.59)
2.98 (1.33, 6.70)
3.16 (1.29, 7.72)
2.72 (1.64, 4.50)
1.12 (0.78, 1.61)
3.26 (1.37, 7.74)
1.02 (0.49, 2.14)
2.55 (0.89, 7.30)
1.54 (0.79, 2.99)
1.82 (0.81, 4.10)
0.44 (0.02, 7.89)
8.33
7.30
13.58
16.89
7.62
9.36
5.79
%
10.50
8.28
0.99
2.98 (1.33, 6.70)
3.16 (1.29, 7.72)
2.72 (1.64, 4.50)
1.12 (0.78, 1.61)
3.15 (1.06, 9.32)
1.02 (0.49, 2.14)
2.55 (0.89, 7.30)
OR (95% CI)
1.54 (0.79, 2.99)
1.82 (0.81, 4.10)
0.44 (0.02, 7.89)
8.33
7.30
13.58
16.89
7.62
9.36
5.79
Weight,
10.50
8.28
0.99
1.05 1 5 10
Crohn’s disease
Supplementary Figure 23. Detailed meta-analysis of Arg702Trp on the basis of allele frequencies. Crohn’s disease. Sporadic cases.
Random effect
Fixed effect 1.74 (1.41, 2.14)
Odds ratio (95% CI)
Esters N (2004)
Zhou Z (2002)
Helio T (2003)
Cuthbert AP (2002)
Annese V (2005)
Buhner S (2006)
Tukel T (2004)
Cottone M (2006)
Study
Vermeire S (2002)
Kugathasan S (2005)
2.28 (1.43, 3.62)
1.21 (0.72, 2.05)
1.09 (0.56, 2.14)
7.61 (0.36, 158.95)
6.71 (2.03, 22.14)
2.94 (1.42, 6.10)
OR (95% CI)
1.59 (0.58, 4.35)
4.01 (1.61, 9.99)
7.71 (1.00, 59.25)
0.96 (0.05, 18.98)
16.42
14.13
1.75
7.92
13.24
Weight,
8.08
9.74
10.77
%
3.55
1.81
1.21 (0.72, 2.05)
1.09 (0.56, 2.14)
7.61 (0.36, 158.95)
6.71 (2.03, 22.14)
2.94 (1.42, 6.10)
2.63 (0.57, 12.19)
1.59 (0.58, 4.35)
4.01 (1.61, 9.99)
7.71 (1.00, 59.25)
0.96 (0.05, 18.98)
16.42
14.13
1.75
7.92
13.24
8.08
9.74
10.77
3.55
1.81
1.05 1 5 10
Supplementary Figure 24. Detailed meta-analysis of Gly908Arg on the basis of allele frequencies. Crohn’s disease. Sporadic cases.
Crohn’s disease
Random effect
Fixed effect 2.11 (1.59, 2.80)
Odds ratio (95% CI)
Annese V (2005)
Buhner S (2006)
Hampe J (2001)
Study
Cottone M (2006)
Cuthbert AP (2002)
Tukel T (2004)
Vermeire S (2002)
Zhou Z (2002)
Esters N (2004)
Helio T (2003)
Kugathasan S (2005)
3.41 (2.24, 5.20)
13.01 (3.92, 43.20)
4.11 (2.59, 6.54)
4.26 (1.82, 9.98)
3.23 (1.72, 6.10)
1.87 (0.60, 5.80)
18.96 (2.56, 140.25)
1.48 (0.67, 3.25)
1.85 (1.12, 3.06)
2.16 (0.95, 4.92)
7.06 (0.43, 115.39)
OR (95% CI)
7.07
5.71
13.04
%
9.64
11.55
7.51
3.61
10.18
12.68
9.89
2.09
Weight,
13.01 (3.92, 43.20)
18.74 (2.53, 138.9)
4.11 (2.59, 6.54)
4.26 (1.82, 9.98)
3.23 (1.72, 6.10)
1.87 (0.60, 5.80)
18.96 (2.56, 140.25)
1.48 (0.67, 3.25)
1.85 (1.12, 3.06)
2.16 (0.95, 4.92)
7.06 (0.43, 115.39)
7.07
5.71
13.04
9.64
11.55
7.51
3.61
10.18
12.68
9.89
2.09
1.05 1 5 10 50
Crohn’s disease
Supplementary Figure 25. Detailed meta-analysis of Leu1007fsincC on the basis of allele frequencies. Crohn’s disease. Sporadic cases
Random effect
Fixed effect 3.49 (2.77, 4.40)
Odds ratio (95% CI)
Supplementary Figure 26. Detailed meta-analysis of Arg702Trp heterozygotes versus non-carriers. Crohn’s disease. All studies.
Random effect
Fixed effect
Hradsky O (2008)
Cuthbert AP (2002)
de Ridder L (2007)
Crawford NPS (2007)
Magyari L (2009)
Ferreira AC (2005)
Derakhshan F (2008)
Tukel T (2004)
Economou M (2007)
Cucchiara S (2007)
Vavassori P (2004)
Leung E (2005)
Rigoli L (2008)
Baptista ML (2008)
Zouiten-Mekki L (2005)
Jess T (2005)
Buning C (2005)
Ferraris A (2006)
Rodrigo L (2007)
Giachino D (2004)
Ozen SC (2006)
Canto E (2007)
Lakatos PL (2005)
Mascheretti S (2002)
Cavanaugh JA (2003)
Ince AT (2008)
van der Linde K (2007)
Tukel T (2004)
Ernst A (2007)
Kugathasan S (2005)
Zaahl MG (2005)
Kugathasan S (2005)
Helio T (2003)
Oostenbrug LE (2006)
Brant SR (2007)
Bianchi V (2007)
Gazouli M (2004)
Study
Buhner S (2006)
Heresbach D (2004)
Vind I (2005)
Bene J (2006)
Braat H (2005)
2.24 (1.89, 2.64)
1.44 (0.91, 2.27)
2.46 (1.44, 4.21)
2.71 (1.55, 4.75)
4.90 (1.45, 16.58)
2.35 (0.91, 6.11)
3.54 (2.09, 5.98)
23.59 (5.02, 110.98)
1.72 (0.70, 4.26)
2.26 (0.66, 7.77)
3.19 (1.86, 5.47)
0.76 (0.11, 5.47)
1.56 (0.81, 3.00)
4.76 (1.76, 12.89)
OR (95% CI)
4.10 (2.14, 7.86)
3.56 (0.41, 31.00)
4.30 (1.20, 15.50)
2.36 (1.07, 5.20)
4.45 (1.84, 10.77)
0.69 (0.30, 1.58)
1.30 (0.71, 2.40)
0.75 (0.13, 4.21)
6.72 (1.51, 29.97)
1.51 (0.78, 2.92)
1.72 (1.09, 2.70)
2.16 (1.36, 3.44)
0.19 (0.02, 1.64)
1.58 (0.68, 3.69)
7.52 (1.07, 52.83)
1.79 (1.13, 2.83)
1.28 (0.74, 2.19)
2.64 (0.72, 9.66)
0.53 (0.06, 4.82)
1.87 (0.87, 4.03)
2.04 (1.26, 3.31)
2.96 (1.70, 5.15)
2.00 (0.99, 4.04)
12.25 (2.82, 53.26)
2.46 (0.79, 7.68)
3.52 (1.52, 8.13)
0.82 (0.28, 2.34)
3.23 (0.67, 15.68)
3.08 (1.44, 6.59)
4.25
3.79
3.67
1.44
2.06
3.85
0.98
2.20
1.41
3.77
0.64
3.19
1.94
Weight
3.21
0.54
1.34
2.60
2.27
2.47
3.39
0.82
1.04
3.16
4.29
4.21
0.55
2.40
0.66
4.24
3.78
1.31
0.52
2.69
4.10
3.70
2.96
1.07
1.60
2.43
1.79
0.95
2.71
1.44 (0.91, 2.27)
2.46 (1.44, 4.21)
2.71 (1.55, 4.75)
4.90 (1.45, 16.58)
2.35 (0.91, 6.11)
3.54 (2.09, 5.98)
23.59 (5.02, 110.98)
1.72 (0.70, 4.26)
2.26 (0.66, 7.77)
3.19 (1.86, 5.47)
0.76 (0.11, 5.47)
1.56 (0.81, 3.00)
4.76 (1.76, 12.89)
OR (95% CI)
4.10 (2.14, 7.86)
3.56 (0.41, 31.00)
4.30 (1.20, 15.50)
2.36 (1.07, 5.20)
4.45 (1.84, 10.77)
0.69 (0.30, 1.58)
1.30 (0.71, 2.40)
0.75 (0.13, 4.21)
6.72 (1.51, 29.97)
1.51 (0.78, 2.92)
1.72 (1.09, 2.70)
2.16 (1.36, 3.44)
0.19 (0.02, 1.64)
1.58 (0.68, 3.69)
7.52 (1.07, 52.83)
1.79 (1.13, 2.83)
1.28 (0.74, 2.19)
2.64 (0.72, 9.66)
0.53 (0.06, 4.82)
1.87 (0.87, 4.03)
2.04 (1.26, 3.31)
2.96 (1.70, 5.15)
2.00 (0.99, 4.04)
12.25 (2.82, 53.26)
2.46 (0.79, 7.68)
3.52 (1.52, 8.13)
0.82 (0.28, 2.34)
3.23 (0.67, 15.68)
3.08 (1.44, 6.59)
4.25
3.79
3.67
1.44
2.06
3.85
0.98
2.20
1.41
3.77
0.64
3.19
1.94
Weight, %
3.21
0.54
1.34
2.60
2.27
2.47
3.39
0.82
1.04
3.16
4.29
4.21
0.55
2.40
0.66
4.24
3.78
1.31
0.52
2.69
4.10
3.70
2.96
1.07
1.60
2.43
1.79
0.95
2.71
1.1 .5 1 2 3 4 5 10 20 50
Odds ratio (95% CI)
Crohn’s disease
2.23 (1.99, 2.49)
Supplementary Figure 27. Detailed meta-analysis of Arg702Trp homozygotes versus non-carriers. Crohn’s disease. All studies.
Studies were excluded from meta-analysis if the risk allele/genotype was found neither in cases nor in controls.
Random effect Fixed effect
Leung E (2005)
Ince AT (2008)
Vind I (2005)
Zouiten-Mekki L (2005)
Lakatos PL (2005)
Bianchi V (2007)
Buhner S (2006)
Zaahl MG (2005)
Crawford NPS (2007)
Helio T (2003)
Kugathasan S (2005)
Derakhshan F (2008)
Tukel T (2004)
Mascheretti S (2002)
Jess T (2005)
de Ridder L (2007)
Bene J (2006)
Giachino D (2004)
Oostenbrug LE (2006)
Heresbach D (2004)
Rodrigo L (2007)
van der Linde K (2007)
Braat H (2005)
Magyari L (2009)
Kugathasan S (2005)
Hradsky O (2008)
Ferraris A (2006)Tukel T (2004)
Brant SR (2007)
Cucchiara S (2007)
Buning C (2005)
Cuthbert AP (2002)
Ernst A (2007)
Economou M (2007)
Ozen SC (2006)
Gazouli M (2004)
Ferreira AC (2005)
Baptista ML (2008)
Cavanaugh JA (2003)
Rigoli L (2008)
Vavassori P (2004)
Canto E (2007)
Study Crohn’s disease
3.18 (1.97, 5.14)
1.06 (0.07, 17.14)
0.38 (0.02, 9.57)
2.28 (0.14, 36.97)
(Excluded)
13.33 (0.80, 223.39)
1.00 (0.06, 16.14)
4.07 (0.21, 80.27)
(Excluded)
1.48 (0.06, 36.65)
(Excluded)
0.94 (0.10, 8.48)
(Excluded)
(Excluded)
8.21 (1.06, 63.93)
(Excluded)
6.59 (0.83, 52.33)
0.72 (0.04, 11.79)
7.09 (0.36, 138.42)
OR (95% CI)
1.55 (0.30, 8.05)
0.55 (0.03, 8.86)
1.22 (0.05, 30.38)
(Excluded)
3.03 (0.38, 24.46)
0.42 (0.04, 4.12)
(Excluded)
4.53 (0.18, 111.49)
4.24 (0.17, 104.98)9.00 (0.36, 223.22)
18.35 (1.01, 333.77)
10.49 (1.22, 90.57)
7.63 (0.36, 160.12)
9.51 (0.53, 169.60)
10.92 (0.52, 228.16)
7.90 (0.40, 155.15)
(Excluded)
(Excluded)
4.78 (0.49, 46.34)
(Excluded)
26.05 (1.48, 458.34)
(Excluded)
2.28 (0.09, 56.45)
1.93 (0.08, 48.27)
2.98
2.23
2.97
0.00
2.90
2.98
2.59
0.00
2.23
0.00
4.77
0.00
0.00
5.47
0.00
5.37
2.95
2.61
Weight
8.49
2.97
2.23
0.00
5.28
4.44
0.00
2.25
2.242.24
2.74
4.96
2.49
2.78
2.50
2.60
0.00
0.00
4.47
0.00
2.80
0.00
2.24
2.22
1.06 (0.07, 17.14)
0.38 (0.02, 9.57)
2.28 (0.14, 36.97)
(Excluded)
13.33 (0.80, 223.39)
1.00 (0.06, 16.14)
4.07 (0.21, 80.27)
(Excluded)
1.48 (0.06, 36.65)
(Excluded)
0.94 (0.10, 8.48)
(Excluded)
(Excluded)
8.21 (1.06, 63.93)
(Excluded)
6.59 (0.83, 52.33)
0.72 (0.04, 11.79)
7.09 (0.36, 138.42)
1.55 (0.30, 8.05)
0.55 (0.03, 8.86)
1.22 (0.05, 30.38)
(Excluded)
3.03 (0.38, 24.46)
0.42 (0.04, 4.12)
(Excluded)
4.53 (0.18, 111.49)
4.24 (0.17, 104.98)9.00 (0.36, 223.22)
18.35 (1.01, 333.77)
10.49 (1.22, 90.57)
7.63 (0.36, 160.12)
9.51 (0.53, 169.60)
10.92 (0.52, 228.16)
7.90 (0.40, 155.15)
(Excluded)
(Excluded)
4.78 (0.49, 46.34)
(Excluded)
26.05 (1.48, 458.34)
(Excluded)
2.28 (0.09, 56.45)
1.93 (0.08, 48.27)
2.98
2.23
2.97
0.00
2.90
2.98
2.59
0.00
2.23
0.00
4.77
0.00
0.00
5.47
0.00
5.37
2.95
2.61
Weight, %
8.49
2.97
2.23
0.00
5.28
4.44
0.00
2.25
2.242.24
2.74
4.96
2.49
2.78
2.50
2.60
0.00
0.00
4.47
0.00
2.80
0.00
2.24
2.22
1.01 .5 1 2 5 10 20 50 100 800
Odds ratio (95% CI)
3.85 (2.50, 5.93)
Supplementary Figure 28. Detailed meta-analysis of Gly908Arg heterozygotes versus non-carriers. Crohn’s disease. All studies.
Studies were excluded from meta-analysis if the risk allele/genotype was found neither in cases nor in controls.
Random effect
Fixed effect
I
Mascheretti S (2002)
Buning C (2005)
Cuthbert AP (2002)
de Ridder L (2007)
Queiroz DM, (2009)
Rigoli L (2008)
Leung E (2005)
Gazouli M (2004)
Tukel T (2004)
Lakatos PL (2005)
Kugathasan S (2005)Braat H (2005)
Ferreira AC (2005)
Giachino D (2004)
Oostenbrug LE (2006)
Canto E (2007)
Cucchiara S (2007)
Ferraris A (2006)
Jess T (2005)
Baptista ML (2008)
Ince AT (2008)
Zouiten-Mekki L (2005)
Derakhshan F (2008)
Cavanaugh JA (2003)
Buhner S (2006)
Brant SR (2007)
Zaahl MG (2005)
Rodrigo L (2007)
Vavassori P (2004)
Magyari L (2009)
Economou M (2007)
Vind I (2005)
van der Linde K (2007)
Tukel T (2004)
Hradsky O (2008)
Crawford NPS (2007)
Ozen SC (2006)Bene J (2006)
Heresbach D (2004)
Kugathasan S (2005)
Study Crohn’s disease
Helio T (2003)
Bianchi V (2007)
Ernst A (2007)
2.34 (1.95, 2.81)
OR (95% CI)
2.07 (1.13, 3.79)
2.63 (0.86, 8.01)
6.32 (1.90, 20.99)
1.40 (0.78, 2.53)
5.45 (1.63, 18.16)
1.13 (0.46, 2.76)
1.93 (0.75, 4.96)
4.89 (2.05, 11.65)
2.70 (1.37, 5.32)
1.84 (0.80, 4.23)
4.50 (2.32, 8.72)0.87 (0.44, 1.70)
1.88 (0.75, 4.76)
3.28 (1.17, 9.14)
1.76 (0.96, 3.22)
6.01 (0.33, 110.83)
2.69 (1.43, 5.06)
5.14 (1.66, 15.89)
2.38 (0.37, 15.11)
1.20 (0.43, 3.37)
0.61 (0.05, 6.92)
2.05 (0.71, 5.91)
5.44 (0.96, 31.01)
3.44 (1.29, 9.16)
2.73 (0.58, 12.85)
4.19 (1.73, 10.14)
0.80 (0.03, 20.02)
1.29 (0.25, 6.50)
2.42 (0.85, 6.84)
5.88 (1.24, 27.75)
0.82 (0.37, 1.82)
3.16 (0.69, 14.45)
10.50 (1.35, 81.62)
4.22 (0.70, 25.63)
2.45 (1.26, 4.74)
8.21 (1.07, 62.71)
0.76 (0.07, 8.60)3.58 (0.41, 31.65)
2.06 (0.57, 7.43)
(Excluded)
7.83 (0.40, 152.36)
4.97 (1.41, 17.49)
1.44 (0.66, 3.12)
Weight, %
5.08
2.17
1.92
5.20
1.91
3.06
2.82
3.18
4.42
3.38
4.564.49
2.89
2.48
5.07
0.38
4.80
2.13
0.90
2.45
0.54
2.36
1.00
2.66
1.24
3.11
0.31
1.14
2.42
1.23
3.62
1.28
0.74
0.94
4.57
0.75
0.540.66
1.73
0.00
0.37
1.78
3.71
2.07 (1.13, 3.79)
2.63 (0.86, 8.01)
6.32 (1.90, 20.99)
1.40 (0.78, 2.53)
5.45 (1.63, 18.16)
1.13 (0.46, 2.76)
1.93 (0.75, 4.96)
4.89 (2.05, 11.65)
2.70 (1.37, 5.32)
1.84 (0.80, 4.23)
4.50 (2.32, 8.72)0.87 (0.44, 1.70)
1.88 (0.75, 4.76)
3.28 (1.17, 9.14)
1.76 (0.96, 3.22)
6.01 (0.33, 110.83)
2.69 (1.43, 5.06)
5.14 (1.66, 15.89)
2.38 (0.37, 15.11)
1.20 (0.43, 3.37)
0.61 (0.05, 6.92)
2.05 (0.71, 5.91)
5.44 (0.96, 31.01)
3.44 (1.29, 9.16)
2.73 (0.58, 12.85)
4.19 (1.73, 10.14)
0.80 (0.03, 20.02)
1.29 (0.25, 6.50)
2.42 (0.85, 6.84)
5.88 (1.24, 27.75)
0.82 (0.37, 1.82)
3.16 (0.69, 14.45)
10.50 (1.35, 81.62)
4.22 (0.70, 25.63)
2.45 (1.26, 4.74)
8.21 (1.07, 62.71)
0.76 (0.07, 8.60)3.58 (0.41, 31.65)
2.06 (0.57, 7.43)
(Excluded)
7.83 (0.40, 152.36)
4.97 (1.41, 17.49)
1.44 (0.66, 3.12)
5.08
2.17
1.92
5.20
1.91
3.06
2.82
3.18
4.42
3.38
4.564.49
2.89
2.48
5.07
0.38
4.80
2.13
0.90
2.45
0.54
2.36
1.00
2.66
1.24
3.11
0.31
1.14
2.42
1.23
3.62
1.28
0.74
0.94
4.57
0.75
0.540.66
1.73
0.00
0.37
1.78
3.71
1.01 .5 1 2 3 5 10 20 50 100 400
Odds ratio (95% CI)
2.33 (2.01, 2.71)
Supplementary Figure 29. Detailed meta-analysis of Gly908Arg homozygotes versus non-carriers. Crohn’s disease. All studies.
Studies were excluded from meta-analysis if the risk allele/genotype was found neither in cases nor in controls.
Random effect
Fixed effect
Magyari L (2009)
Braat H (2005)
Rodrigo L (2007)
Oostenbrug LE (2006)
Heresbach D (2004)
Crawford NPS (2007)
Lakatos PL (2005)
Vind I (2005)
Ferraris A (2006)
Queiroz DM, (2009)
Vavassori P (2004)
Giachino D (2004)
Ernst A (2007)
Ince AT (2008)
Zaahl MG (2005)
Gazouli M (2004)
Brant SR (2007)
Kugathasan S (2005)
Buhner S (2006)
Economou M (2007)
Derakhshan F (2008)
van der Linde K (2007)
Ozen SC (2006)
Ferreira AC (2005)
Tukel T (2004)
Bene J (2006)
Bianchi V (2007)
Kugathasan S (2005)
Hradsky O (2008)
Mascheretti S (2002)
de Ridder L (2007)
Helio T (2003)
Cuthbert AP (2002)
Canto E (2007)
Jess T (2005)
Cavanaugh JA (2003)
Tukel T (2004)
Buning C (2005)
Leung E (2005)
Cucchiara S (2007)
Rigoli L (2008)
Baptista ML (2008)
Zouiten-Mekki L (2005)
Study Crohn’s disease
2.35 (1.16, 4.76)
6.52 (0.31, 137.23)
3.00 (0.16, 56.11)
(Excluded)
0.29 (0.03, 3.25)
1.43 (0.06, 35.53)
0.16 (0.01, 4.00)
(Excluded)
(Excluded)
9.58 (0.49, 187.33)
(Excluded)
2.42 (0.10, 59.89)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
3.21 (0.13, 79.74)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
4.58 (0.18, 113.98)
4.11 (0.17, 101.25)
(Excluded)
3.59 (0.17, 76.52)
(Excluded)
OR (95% CI)
(Excluded)
6.12 (0.68, 55.00)
(Excluded)
1.08 (0.18, 6.52)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
35.31 (1.30, 956.57)
(Excluded)
0.35 (0.01, 8.57)
9.66 (0.46, 202.40)
(Excluded)
(Excluded)
(Excluded)
5.35
5.79
0.00
8.58
4.82
4.82
0.00
0.00
5.62
0.00
4.82
0.00
0.00
0.00
0.00
4.81
0.00
0.00
0.00
0.00
0.00
0.00
4.80
4.83
0.00
5.31
0.00
Weight
0.00
10.30
0.00
15.39
0.00
0.00
0.00
0.00
0.00
4.56
0.00
4.83
5.37
0.00
0.00
0.00
2.35 (1.16, 4.76)
6.52 (0.31, 137.23)
3.00 (0.16, 56.11)
(Excluded)
0.29 (0.03, 3.25)
1.43 (0.06, 35.53)
0.16 (0.01, 4.00)
(Excluded)
(Excluded)
9.58 (0.49, 187.33)
(Excluded)
2.42 (0.10, 59.89)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
3.21 (0.13, 79.74)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
4.58 (0.18, 113.98)
4.11 (0.17, 101.25)
(Excluded)
3.59 (0.17, 76.52)
(Excluded)
OR (95% CI)
(Excluded)
6.12 (0.68, 55.00)
(Excluded)
1.08 (0.18, 6.52)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
35.31 (1.30, 956.57)
(Excluded)
0.35 (0.01, 8.57)
9.66 (0.46, 202.40)
(Excluded)
(Excluded)
(Excluded)
5.35
5.79
0.00
8.58
4.82
4.82
0.00
0.00
5.62
0.00
4.82
0.00
0.00
0.00
0.00
4.81
0.00
0.00
0.00
0.00
0.00
0.00
4.80
4.83
0.00
5.31
0.00
Weigh, %
0.00
10.30
0.00
15.39
0.00
0.00
0.00
0.00
0.00
4.56
0.00
4.83
5.37
0.00
0.00
0.00
1.01 1 5 10 50 100 200
Odds ratio (95% CI)
2.35 (1.26, 4.38)
Supplementary Figure 30. Detailed meta-analysis of Leu1007fsincC heterozygotes versus non-carriers. Crohn’s disease. All studies.
Random effect
Fixed effect
Buning C (2005)
Rodrigo L (2007)
Guo QS (2004)
Jess T (2005)
Braat H (2005)
Crawford NPS (2007)
Brant SR (2007)
Mascheretti S (2002)
Rigoli L (2008)
Murillo L (2002)
Cuthbert AP (2002)
Derakhshan F (2008)
Gazouli M (2004)
Economou M (2007)
van der Linde K (2007)
Ferreira AC (2005)
Helio T (2003)
Zouiten-Mekki L (2005)
Zaahl MG (2005)
Ferraris A (2006)
Roussomoustakaki M (2003)
Heresbach D (2004)
Kugathasan S (2005)
Canto E (2007)
Ogura Y (2001)
Bianchi V (2007)
Cucchiara S (2007)
Hradsky O (2008)
Radlmayr M (2002)
Kugathasan S (2005)
Study Crohn’s disease
Vavassori P (2004)
Baptista ML (2008)
Oostenbrug LE (2006)
Leung E (2005)
Vind I (2005)
Buhner S (2006)
Ince AT (2008)
Queiroz DM, (2009)
de Ridder L (2007)
Tukel T (2004)
Ernst A (2007)
Magyari L (2009)
Cavanaugh JA (2003)
Ozen SC (2006)
Hampe J (2001)
Lakatos PL (2005)
Giachino D (2004)
Tukel T (2004)
Bene J (2006)
3.26 (2.80, 3.81)
3.99 (1.78, 8.94)
1.77 (0.49, 6.38)
12.21 (0.72, 205.91)
1.14 (0.24, 5.46)
2.30 (1.06, 4.97)
2.62 (0.97, 7.05)
2.94 (1.61, 5.37)
2.02 (1.26, 3.23)
OR (95% CI)
3.93 (1.55, 9.95)
7.16 (2.04, 25.17)
2.62 (1.35, 5.06)
2.58 (0.35, 18.97)
3.62 (1.77, 7.40)
6.23 (2.86, 13.58)
5.03 (1.43, 17.64)
2.89 (1.33, 6.30)
2.34 (1.07, 5.09)
4.97 (0.25, 97.37)
0.33 (0.04, 2.79)
6.61 (2.19, 19.94)
1.84 (0.30, 11.42)
1.56 (0.68, 3.61)
2.16 (0.13, 35.12)
4.40 (0.54, 36.25)
1.47 (0.87, 2.49)
6.08 (1.76, 21.03)
4.44 (2.13, 9.24)
3.11 (2.11, 4.57)
7.45 (2.44, 22.75)
6.87 (3.99, 11.84)
6.93 (2.03, 23.65)
4.69 (1.50, 14.62)
2.43 (1.37, 4.30)
11.87 (3.55, 39.65)
3.46 (1.34, 8.92)
14.28 (1.88, 108.68)
1.24 (0.08, 20.24)
9.20 (1.49, 56.67)
1.77 (1.00, 3.12)
3.62 (1.70, 7.71)
3.06 (1.67, 5.60)
3.85 (1.56, 9.51)
5.97 (2.68, 13.32)
7.77 (0.37, 164.39)
2.59 (1.56, 4.32)
3.98 (2.02, 7.82)
1.92 (0.79, 4.65)
55.00 (2.41, 1254.33)
3.50 (0.94, 13.01)
2.51
1.23
0.29
0.86
2.67
1.86
3.63
4.61
Weight
2.05
1.27
3.26
0.55
2.95
2.63
1.27
2.63
2.64
0.26
0.49
1.57
0.65
2.39
0.29
0.50
4.17
1.29
2.86
5.37
1.54
4.03
1.32
1.50
3.83
1.36
1.99
0.54
0.29
0.66
3.85
2.75
3.60
2.13
2.53
0.25
4.29
3.16
2.21
0.24
1.17
3.26 (2.80, 3.81)
3.99 (1.78, 8.94)
1.77 (0.49, 6.38)
12.21 (0.72, 205.91)
1.14 (0.24, 5.46)
2.30 (1.06, 4.97)
2.62 (0.97, 7.05)
2.94 (1.61, 5.37)
2.02 (1.26, 3.23)
OR (95% CI)
3.93 (1.55, 9.95)
7.16 (2.04, 25.17)
2.62 (1.35, 5.06)
2.58 (0.35, 18.97)
3.62 (1.77, 7.40)
6.23 (2.86, 13.58)
5.03 (1.43, 17.64)
2.89 (1.33, 6.30)
2.34 (1.07, 5.09)
4.97 (0.25, 97.37)
0.33 (0.04, 2.79)
6.61 (2.19, 19.94)
1.84 (0.30, 11.42)
1.56 (0.68, 3.61)
2.16 (0.13, 35.12)
4.40 (0.54, 36.25)
1.47 (0.87, 2.49)
6.08 (1.76, 21.03)
4.44 (2.13, 9.24)
3.11 (2.11, 4.57)
7.45 (2.44, 22.75)
6.87 (3.99, 11.84)
6.93 (2.03, 23.65)
4.69 (1.50, 14.62)
2.43 (1.37, 4.30)
11.87 (3.55, 39.65)
3.46 (1.34, 8.92)
14.28 (1.88, 108.68)
1.24 (0.08, 20.24)
9.20 (1.49, 56.67)
1.77 (1.00, 3.12)
3.62 (1.70, 7.71)
3.06 (1.67, 5.60)
3.85 (1.56, 9.51)
5.97 (2.68, 13.32)
7.77 (0.37, 164.39)
2.59 (1.56, 4.32)
3.98 (2.02, 7.82)
1.92 (0.79, 4.65)
55.00 (2.41, 1254.33)
3.50 (0.94, 13.01)
2.51
1.23
0.29
0.86
2.67
1.86
3.63
4.61
Weight, %
2.05
1.27
3.26
0.55
2.95
2.63
1.27
2.63
2.64
0.26
0.49
1.57
0.65
2.39
0.29
0.50
4.17
1.29
2.86
5.37
1.54
4.03
1.32
1.50
3.83
1.36
1.99
0.54
0.29
0.66
3.85
2.75
3.60
2.13
2.53
0.25
4.29
3.16
2.21
0.24
1.17
1.01 .5 1 2 3 5 10 20 50 100 400
Odds ratio (95% CI)
3.17 (2.82, 3.57)
Supplementary Figure 31. Detailed meta-analysis of Leu1007fsincC homozygotes versus non-carriers. Crohn’s disease. All studies.
Studies were excluded from meta-analysis if the risk allele/genotype was found neither in cases nor in controls.Odds ratio (95% CI)
Random effect
Fixed effect
Bene J (2006)
Economou M (2007)
Hradsky O (2008)
Baptista ML (2008)
Cuthbert AP (2002)
Canto E (2007)
van der Linde K (2007)
Bianchi V (2007)
Ferraris A (2006)
Kugathasan S (2005)
Oostenbrug LE (2006)
Study Crohn’s disease
Derakhshan F (2008)
Ozen SC (2006)
de Ridder L (2007)
Jess T (2005)
Giachino D (2004)Cavanaugh JA (2003)
Zaahl MG (2005)
Ernst A (2007)
Vind I (2005)
Rodrigo L (2007)Rigoli L (2008)
Buning C (2005)
Brant SR (2007)
Vavassori P (2004)
Leung E (2005)
Ferreira AC (2005)Heresbach D (2004)
Tukel T (2004)
Queiroz DM, (2009)
Helio T (2003)
Zouiten-Mekki L (2005)
Hampe J (2001)
Ince AT (2008)
Tukel T (2004)
Magyari L (2009)Radlmayr M (2002)
Cucchiara S (2007)
Murillo L (2002)
Buhner S (2006)
Gazouli M (2004)
Mascheretti S (2002)
Lakatos PL (2005)Ogura Y (2001)
Roussomoustakaki M (2003)
Guo QS (2004)
Braat H (2005)
Crawford NPS (2007)
Kugathasan S (2005)
9.59 (5.83, 15.77)
7.28 (0.38, 138.67)
29.30 (1.66, 518.07)
113.11 (6.88, 1859.45)
(Excluded)
9.50 (0.53, 169.37)
(Excluded)
5.56 (0.28, 109.39)
(Excluded)
(Excluded)
32.41 (1.66, 631.50)
7.53 (0.97, 58.22)
(Excluded)
(Excluded)
OR (95% CI)
1.73 (0.33, 8.99)
(Excluded)
9.22 (0.49, 172.55)15.34 (0.82, 286.26)
(Excluded)
46.93 (2.74, 803.04)
0.83 (0.03, 20.71)
(Excluded)(Excluded)
17.91 (0.98, 326.81)
4.81 (0.20, 118.74)
13.56 (0.77, 239.92)
(Excluded)
18.77 (1.05, 335.00)6.52 (0.36, 117.04)
16.90 (0.80, 356.20)
68.16 (3.22, 1444.37)
8.18 (0.42, 159.19)
(Excluded)
44.78 (2.69, 744.74)
(Excluded)
(Excluded)
12.73 (0.68, 239.21)14.07 (0.75, 265.20)
5.85 (0.24, 144.41)
9.39 (0.48, 183.55)
7.16 (0.39, 131.78)
5.57 (0.26, 117.70)
8.25 (0.45, 149.65)
12.09 (0.71, 204.40)16.92 (0.99, 288.44)
(Excluded)
(Excluded)
1.81 (0.09, 37.87)
1.46 (0.06, 36.21)
(Excluded)
2.85
3.00
3.15
0.00
2.98
0.00
2.79
0.00
0.00
2.80
5.91
0.00
0.00
Weight
9.10
0.00
2.882.89
0.00
3.06
2.40
0.000.00
2.93
2.41
2.99
0.00
2.982.96
2.66
2.65
2.81
0.00
3.13
0.00
0.00
2.872.87
2.41
2.80
2.91
2.65
2.94
3.093.07
0.00
0.00
2.67
2.40
0.00
9.59 (5.83, 15.77)
7.28 (0.38, 138.67)
29.30 (1.66, 518.07)
113.11 (6.88, 1859.45)
(Excluded)
9.50 (0.53, 169.37)
(Excluded)
5.56 (0.28, 109.39)
(Excluded)
(Excluded)
32.41 (1.66, 631.50)
7.53 (0.97, 58.22)
(Excluded)
(Excluded)
OR (95% CI)
1.73 (0.33, 8.99)
(Excluded)
9.22 (0.49, 172.55)15.34 (0.82, 286.26)
(Excluded)
46.93 (2.74, 803.04)
0.83 (0.03, 20.71)
(Excluded)(Excluded)
17.91 (0.98, 326.81)
4.81 (0.20, 118.74)
13.56 (0.77, 239.92)
(Excluded)
18.77 (1.05, 335.00)6.52 (0.36, 117.04)
16.90 (0.80, 356.20)
68.16 (3.22, 1444.37)
8.18 (0.42, 159.19)
(Excluded)
44.78 (2.69, 744.74)
(Excluded)
(Excluded)
12.73 (0.68, 239.21)14.07 (0.75, 265.20)
5.85 (0.24, 144.41)
9.39 (0.48, 183.55)
7.16 (0.39, 131.78)
5.57 (0.26, 117.70)
8.25 (0.45, 149.65)
12.09 (0.71, 204.40)16.92 (0.99, 288.44)
(Excluded)
(Excluded)
1.81 (0.09, 37.87)
1.46 (0.06, 36.21)
(Excluded)
2.85
3.00
3.15
0.00
2.98
0.00
2.79
0.00
0.00
2.80
5.91
0.00
0.00
Weight, %
9.10
0.00
2.882.89
0.00
3.06
2.40
0.000.00
2.93
2.41
2.99
0.00
2.982.96
2.66
2.65
2.81
0.00
3.13
0.00
0.00
2.872.87
2.41
2.80
2.91
2.65
2.94
3.093.07
0.00
0.00
2.67
2.40
0.00
1.01 .5 1 10 50 100 200 600
12.17 (7.56, 19.59)
Supplementary Figure 32. Detailed meta-analysis of NOD2/CARD15 simple heterozygtoes versus non-carriers. Crohn’s disease. All studies.
Random effect
Fixed effect
Ferraris A (2006)
Giachino D (2004)
van der Linde K (2007)
Tukel T (2004)Leung E (2005)
Lakatos PL (2005)
Jess T (2005)
Gazouli M (2004)
Cuthbert AP (2002)
Annese V (2005)Zhou Z (2002)Braat H (2005)
Helio T (2003)
Ernst A (2007)
Derakhshan F (2008)
Rodrigo L (2007)
Hugot JP (2001)Heresbach D (2004)
Arnot IDR (2004)
Vind I (2005)
Ahmad T (2002)Brant SR (2007)
Vavassori P (2004)
Cavanaugh JA (2003)
Buhner S (2006)Torkvist L (2006)
Mendoza JL (2003)
Oostenbrug LE (2006)
Tukel T (2004)
Study Crohn’s disease
2.38 (2.03, 2.79)
4.23 (2.19, 8.17)
1.74 (1.05, 2.89)
2.72 (1.32, 5.58)
OR (95% CI)
3.11 (1.76, 5.50)2.23 (1.32, 3.77)
1.97 (1.29, 3.01)
5.36 (1.84, 15.59)
7.00 (3.73, 13.13)
1.87 (1.21, 2.89)
2.42 (1.52, 3.86)1.04 (0.64, 1.67)1.92 (1.18, 3.12)
2.38 (1.33, 4.25)
2.06 (1.45, 2.93)
8.49 (2.92, 24.65)
0.96 (0.49, 1.88)
2.92 (1.63, 5.25)1.93 (1.06, 3.51)
2.06 (1.33, 3.19)
1.78 (0.89, 3.57)
2.40 (1.59, 3.63)2.80 (1.84, 4.28)
3.29 (1.55, 6.96)
1.42 (0.90, 2.23)
6.33 (2.34, 17.13)3.40 (1.35, 8.61)
2.34 (1.24, 4.40)
1.96 (1.34, 2.85)
20.00 (3.48, 115.02)
3.10
3.96
2.81
Weight
3.603.85
4.51
1.66
3.26
4.42
4.234.154.10
3.53
5.00
1.67
3.06
3.503.41
4.43
2.92
4.594.52
2.68
4.32
1.852.04
3.25
4.84
0.74
2.38 (2.03, 2.79)
4.23 (2.19, 8.17)
1.74 (1.05, 2.89)
2.72 (1.32, 5.58)
OR (95% CI)
3.11 (1.76, 5.50)2.23 (1.32, 3.77)
1.97 (1.29, 3.01)
5.36 (1.84, 15.59)
7.00 (3.73, 13.13)
1.87 (1.21, 2.89)
2.42 (1.52, 3.86)1.04 (0.64, 1.67)1.92 (1.18, 3.12)
2.38 (1.33, 4.25)
2.06 (1.45, 2.93)
8.49 (2.92, 24.65)
0.96 (0.49, 1.88)
2.92 (1.63, 5.25)1.93 (1.06, 3.51)
2.06 (1.33, 3.19)
1.78 (0.89, 3.57)
2.40 (1.59, 3.63)2.80 (1.84, 4.28)
3.29 (1.55, 6.96)
1.42 (0.90, 2.23)
6.33 (2.34, 17.13)3.40 (1.35, 8.61)
2.34 (1.24, 4.40)
1.96 (1.34, 2.85)
20.00 (3.48, 115.02)
3.10
3.96
2.81
Weight, %
3.603.85
4.51
1.66
3.26
4.42
4.234.154.10
3.53
5.00
1.67
3.06
3.503.41
4.43
2.92
4.594.52
2.68
4.32
1.852.04
3.25
4.84
0.74
1.01 .5 1 10 50 200 600
Odds ratio (95% CI)
2.25 (2.04, 2.48)
Supplementary Figure 33. Detailed meta-analysis of NOD2/CARD15 compound heterozygtoes versus non-carriers. Crohn’s disease. All studies.
Random effect
Fixed effect
Buhner S (2006)
Cavanaugh JA (2003)
Vind I (2005)
Study Crohn’s disease
Tukel T (2004)
Ernst A (2007)
Hugot JP (2001)
Ferraris A (2006)
Torkvist L (2006)
Zhou Z (2002)
Oostenbrug LE (2006)
Arnot IDR (2004)
Cuthbert AP (2002)Lakatos PL (2005)
van der Linde K (2007)
Helio T (2003)
Heresbach D (2004)
Rodrigo L (2007)
Jess T (2005)
Ahmad T (2002)
Tukel T (2004)
Gazouli M (2004)
Braat H (2005)
Brant SR (2007)
Leung E (2005)
Vavassori P (2004)
Mendoza JL (2003)
Annese V (2005)
Derakhshan F (2008)
8.98 (5.99, 13.47)
4.06 (0.46, 35.75)
90.78 (5.49, 1500.98)
5.12 (0.46, 57.37)
12.50 (0.87, 179.32)
7.10 (1.42, 35.37)
26.80 (1.63, 440.33)
36.91 (2.14, 637.74)
2.67 (0.11, 65.98)
4.88 (0.65, 36.89)
4.95 (1.71, 14.32)
8.77 (1.10, 69.69)
48.66 (2.96, 800.42)25.92 (1.57, 427.92)
16.23 (0.92, 287.11)
5.81 (0.67, 50.37)
2.45 (0.22, 27.14)
15.00 (0.88, 256.96)
(Excluded)
2.50 (0.15, 42.44)
43.12 (5.76, 322.99)
5.11 (1.49, 17.45)
63.16 (3.67, 1087.94)
3.51 (0.80, 15.45)
49.07 (2.89, 834.51)
26.31 (1.53, 453.36)
OR (95% CI)
6.77 (0.35, 132.43)
9.76 (0.55, 173.08)
22.18 (2.97, 165.41)
27.00 (1.35, 540.32)
3.47
2.09
2.81
2.31
6.37
2.10
2.02
1.59
4.01
14.56
3.82
2.092.09
1.99
3.52
2.83
2.03
0.00
2.05
4.05
10.88
2.03
7.48
2.04
2.03
Weight
1.86
1.99
4.07
1.83
8.98 (5.99, 13.47)
4.06 (0.46, 35.75)
90.78 (5.49, 1500.98)
5.12 (0.46, 57.37)
12.50 (0.87, 179.32)
7.10 (1.42, 35.37)
26.80 (1.63, 440.33)
36.91 (2.14, 637.74)
2.67 (0.11, 65.98)
4.88 (0.65, 36.89)
4.95 (1.71, 14.32)
8.77 (1.10, 69.69)
48.66 (2.96, 800.42)25.92 (1.57, 427.92)
16.23 (0.92, 287.11)
5.81 (0.67, 50.37)
2.45 (0.22, 27.14)
15.00 (0.88, 256.96)
(Excluded)
2.50 (0.15, 42.44)
43.12 (5.76, 322.99)
5.11 (1.49, 17.45)
63.16 (3.67, 1087.94)
3.51 (0.80, 15.45)
49.07 (2.89, 834.51)
26.31 (1.53, 453.36)
OR (95% CI)
6.77 (0.35, 132.43)
9.76 (0.55, 173.08)
22.18 (2.97, 165.41)
27.00 (1.35, 540.32)
3.47
2.09
2.81
2.31
6.37
2.10
2.02
1.59
4.01
14.56
3.82
2.092.09
1.99
3.52
2.83
2.03
0.00
2.05
4.05
10.88
2.03
7.48
2.04
2.03
Weight, %
1.86
1.99
4.07
1.83
1.01 .5 1 10 50 200 500
Odds ratio (95% CI)
Giachino D (2004)
12.63 (8.47, 18.83)
Studies were excluded from meta-analysis if the risk allele/genotype was found neither in cases nor in controls.
Supplementary Figure 34. Detailed meta-analysis of NOD2/CARD15 homozygotes versus non-carriers. Crohn’s disease. All studies.
Studies were excluded from meta-analysis if the risk allele/genotype was found neither in cases nor in controls.
Random effect
Fixed effect
Hugot JP (2001)
Cuthbert AP (2002)
Oostenbrug LE (2006)
Torkvist L (2006)
Brant SR (2007)
Helio T (2003)
Zhou Z (2002)
Ferraris A (2006)
Buhner S (2006)
Gazouli M (2004)
Ahmad T (2002)
Tukel T (2004)
Lakatos PL (2005)
Study Crohn’s disease
Annese V (2005)
Vavassori P (2004)
Braat H (2005)
Leung E (2005)
Cavanaugh JA (2003)
Giachino D (2004)
Heresbach D (2004)
Mendoza JL (2003)
Tukel T (2004)
Derakhshan F (2008)Jess T (2005)
van der Linde K (2007)
Vind I (2005)
Ernst A (2007)
Arnot IDR (2004)
Rodrigo L (2007)
6.69 (4.13, 10.85)
18.86 (1.14, 312.08)
20.62 (1.21, 350.00)
2.55 (0.93, 6.96)
6.22 (0.32, 121.50)
25.52 (1.43, 456.02)
8.56 (0.44, 166.48)
3.41 (0.44, 26.35)
15.82 (0.84, 297.37)
13.82 (0.78, 244.65)
15.25 (0.77, 302.88)
13.72 (1.67, 112.55)
29.55 (1.50, 581.73)
29.83 (1.81, 490.84)
12.42 (1.62, 95.43)
18.36 (1.06, 319.16)
5.78 (0.75, 44.50)
0.63 (0.06, 6.99)
42.61 (2.50, 727.03)
17.41 (0.98, 307.89)
OR (95% CI)
4.79 (0.59, 39.02)
8.46 (0.47, 152.06)
64.71 (2.21, 1891.71)
(Excluded)(Excluded)
6.68 (0.34, 132.00)
1.28 (0.11, 14.34)
59.10 (3.49, 1001.40)
1.30 (0.29, 5.86)
1.28 (0.05, 31.81)
2.76
2.71
14.63
2.48
2.62
2.48
4.90
2.54
2.64
2.45
4.66
2.47
2.77
4.92
2.67
4.91
3.65
2.70
2.64
Weight
4.68
2.61
1.95
0.000.00
2.46
3.63
2.72
8.18
2.14
6.69 (4.13, 10.85)
18.86 (1.14, 312.08)
20.62 (1.21, 350.00)
2.55 (0.93, 6.96)
6.22 (0.32, 121.50)
25.52 (1.43, 456.02)
8.56 (0.44, 166.48)
3.41 (0.44, 26.35)
15.82 (0.84, 297.37)
13.82 (0.78, 244.65)
15.25 (0.77, 302.88)
13.72 (1.67, 112.55)
29.55 (1.50, 581.73)
29.83 (1.81, 490.84)
12.42 (1.62, 95.43)
18.36 (1.06, 319.16)
5.78 (0.75, 44.50)
0.63 (0.06, 6.99)
42.61 (2.50, 727.03)
17.41 (0.98, 307.89)
OR (95% CI)
4.79 (0.59, 39.02)
8.46 (0.47, 152.06)
64.71 (2.21, 1891.71)
(Excluded)(Excluded)
6.68 (0.34, 132.00)
1.28 (0.11, 14.34)
59.10 (3.49, 1001.40)
1.30 (0.29, 5.86)
1.28 (0.05, 31.81)
2.76
2.71
14.63
2.48
2.62
2.48
4.90
2.54
2.64
2.45
4.66
2.47
2.77
4.92
2.67
4.91
3.65
2.70
2.64
Weight, %
4.68
2.61
1.95
0.000.00
2.46
3.63
2.72
8.18
2.14
1.01 .5 1 10 50 200 600
Odds ratio (95% CI)
8.08 (5.33, 12.26)